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CHAPTER 1: INTRODUCTION
1.1 Spinocerebellar ataxia type 3
The polyglutamine (polyQ) disorders are a group of nine genetically inherited diseases
caused by CAG triplet repeat expansions in nine distinct genes (Matos et al., 2011). Each disease
gene translates into a protein with an abnormally expanded polyQ tract. These mutated proteins
have increased propensities for misfolding and aggregation, leading to neurotoxicity and
neurodegeneration (Matos et al., 2011). For all polyQ disorders, the length of the polyQ tract is
inversely correlated with the age of onset and directly correlated with disease severity (Costa
Mdo and Paulson, 2012). Huntington’s disease (HD), Spinal-bulbar muscular atrophy (SBMA),
Dentatorubral-pallidoluysian atrophy (DRPLA), and six spinocerebellar ataxias (SCA 1, 2, 3, 6,
7, 17) belong to this class (Table 1.1). All polyQ disorders are dominantly inherited, except for
the X-linked SBMA (Costa Mdo and Paulson, 2012).
SCA3, or Machado-Joseph disease (MJD), is the most common dominantly inherited
ataxia (Costa Mdo and Paulson, 2012). The disease is caused by CAG repeat expansion in the
ATXN3 gene, located on chromosome 14 (Takiyama et al., 1993). As a result, the polyQ tract of
the ataxin-3 protein increases from a normal range of ~10-40 repeats to a disease range of
~60-80 repeats (Costa Mdo and Paulson, 2012; Matos et al., 2011). The primarily degenerated
regions are the cerebellar pathways and nuclei, basal ganglia, midbrain, brainstem, and spinal
cord (Costa Mdo and Paulson, 2012; Matos et al., 2011). Onset of SCA3 occurs in middle to late
life, with symptoms including progressive ataxia accompanied by complications with speech,
swallowing, vision, muscle tone, neuropathy and more (Matos et al., 2011). Over time, the
patients will unfortunately succumb to the disease, since there is currently no cure. This
introduction will review the normal functions of ataxin-3 and the role of protein context in polyQ
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disorders. Both topics can provide insight into aberrant mechanisms in SCA3 to target for
therapeutics.
1.2 Physiological functions of ataxin-3
Ataxin-3 is a deubiquitinating enzyme of the MJD subfamily (Burnett et al., 2003;
Winborn et al., 2008). It is found in both the nucleus and the cytoplasm, and is expressed
ubiquitously throughout the tissues (Costa et al., 2004; Paulson et al., 1997a; Schmidt et al.,
1998; Trottier et al., 1998). As such, ataxin-3 is involved in numerous functions in the cell (Costa
Mdo and Paulson, 2012). It has several distinct domains that mediate its interactions with other
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proteins (Figure 1.1). The cysteine protease domain, called the Josephin domain, is located at the
structured N-terminus (Masino et al., 2003; Masino et al., 2004). Two ubiquitin binding sites
(UbS1/2) are also located in this region to facilitate the recognition and positioning of ubiquitin
(Ub) chains for cleavage (Nicastro et al., 2009; Nicastro et al., 2010). In addition to binding Ub,
UbS2 also binds to the proteasomal shuttle protein, Rad23 (Doss-Pepe et al., 2003; Nicastro et
al., 2005; Wang et al., 2000). Depending on the isoform, two or three ubiquitin-interacting motifs
(UIMs) are located at the flexible C-terminus (Goto et al., 1997; Harris et al., 2010; Schmidt et
al., 1998). These motifs are crucial for ataxin-3’s binding to polyUb chains, as well as its
cleavage specificity (Burnett et al., 2003; Doss-Pepe et al., 2003; Todi et al., 2010). An argininelysine rich motif that is essential for binding to the AAA ATPase, VCP, is located between the
second UIM and the polyQ tract (Boeddrich et al., 2006; Doss-Pepe et al., 2003). This section
will review how ataxin-3’s protein-binding domains facilitate its functions in protein quality
control, transcriptional regulation, and DNA repair. Potential loss- or gain-of-functions that could
contribute to SCA3 will be discussed throughout.
1.2.1 Protein quality control
Ataxin-3 has been implicated in several protein quality control pathways. The most
obvious among them is the ubiquitin proteasome system (UPS), due to ataxin-3’s DUB activity
(Burnett et al., 2003). Ataxin-3 demonstrates cleavage selectivity for chains of 5 or more (Ub)
moieties (Winborn et al., 2008). While this DUB can cleave both K48- and K63-linked Ub
chains in vitro, it shows the greatest catalytic activity towards K63-linkages, especially those
within mixed K48-K63 chains (Winborn et al., 2008). Monoubiquitination of ataxin-3, primarily
at lysine 117, and sumoylation of ataxin-3 at its N-terminus enhance its DUB activity (Pfeiffer et
al., 2017; Todi et al., 2010; Todi et al., 2009). In vivo, ataxin-3 likely modulates the
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ubiquitination status of many proteins, since total levels of ubiquitination are increased in atxn3
knockout mouse brains and ataxin-3-depleted human cell lines, while total ubiquitination levels
are decreased when ataxin-3 is overexpressed in HEK293 cells (Rodrigues et al., 2010;
Scaglione et al., 2011; Schmitt et al., 2007; Winborn et al., 2008).
Ataxin-3 is known to regulate the E3 ligases, C-terminus of Hsc70-interacting protein
(CHIP) and parkin (Durcan et al., 2011; Scaglione et al., 2011; Winborn et al., 2008). Through
Ube2w-mediated monoubiquitination of CHIP, ataxin-3 is recruited to edit the length of polyUb
chains on CHIP substrates (Scaglione et al., 2011). Once polyubiquitinated substrates
accumulate, ataxin-3 deubiquitinates CHIP to end the reaction (Scaglione et al., 2011). Initially,
ataxin-3 was believed to reduce levels of ubiquitinated parkin via the typical deubiquitination
model (Durcan et al., 2011), but further examination suggests that this regulatory mechanism is
more complex. Ataxin-3 appears to bind both parkin and the cooperating E2 enzyme (Ubc7),
stabilize their interaction, and then “re-route” parkin’s self-monoubiquitination reaction onto
ataxin-3 itself (Durcan et al., 2012). This process is still dependent on ataxin-3’s catalytic activity
(Durcan et al., 2012). This proposed mechanism is very interesting, since it suggests ataxin-3 is
capable of 1) an atypical mechanism of deubiquitination and 2) regulating E2 enzymes, not just
E3s. In the cases of both parkin and CHIP, deubiquitination is partially mediated by ataxin-3’s
UIMs (Bai et al., 2013; Scaglione et al., 2011). PolyQ-expansion of ataxin-3 seems to heighten
both interactions, which correlates with decreased levels of these E3s in an SCA3 mouse model
(Durcan et al., 2011; Scaglione et al., 2011). Pathogenic ataxin-3 also enhances parkin’s
autophagic degradation in cells, which could explain the decreased levels in the mouse model
(Durcan et al., 2011). Ataxin-3’s normal role in autophagy will be discussed later in this section.
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Table 1.2: Substrates of Ataxin-3
Substrate

Pathway

Regulation by Ataxin-3

Reference

CHIP

Ubiquitination

Ligase activity

Scaglione et al., 2011
Winborn et al., 2008

Parkin

Ubiquitination

Protein stability

Durcan et al., 2011
Durcan et al., 2012

Chk1

DNA repair

Protein stability

Tu et al., 2017

MDC1*

DNA repair

Interaction with DNA

Pfeiffer et al., 2017

Apoptosis

Protein stability

Liu et al., 2016

Autophagy

Protein stability

Ashkenazi et al., 2017

E3 ligases

Cell cycle checkpoint mediators

p53
Autophagy regulators
Beclin-1

*It has not yet been confirmed that ataxin-3 directly deubiquitinates MDC1.

Recently, p53 was discovered to be another substrate of ataxin-3 (Liu et al., 2016). The
authors reported that the N-terminus of ataxin-3 is essential for direct binding to p53, and the
UIMs assist with binding to the ubiquitinated form. Ataxin-3 deubiquitinates p53, stabilizes the
protein by preventing its proteasomal degradation, and promotes transcription of p53-target
genes. Interestingly, pathogenic ataxin-3 has increased binding and DUB activity towards p53.
This enhances p53 stability, transcriptional activity, and neuronal loss in both zebrafish and
mouse brains (Liu et al., 2016). It is worth noting that another lab previously reported that
pathogenic ataxin-3 increased p53 transcriptional activation and subsequent cell death, but this
was not attributed to an increase in p53 protein levels (Chou et al., 2011b). Nevertheless, the
work by Liu et al. is exciting because it demonstrates that ataxin-3 can deubiquitinate proteins
other than ligases (Table 1.2), and these interactions may contribute to SCA3 progression when
the polyQ tract is expanded.
Ataxin-3 physically interacts with polyubiquitinated proteins, the proteasome, and several
shuttle proteins, including Rad23, VCP, and ubiquilin-1 (Boeddrich et al., 2006; Doss-Pepe et al.,
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2003; Heir et al., 2006; Nicastro et al., 2005; Wang et al., 2000). This prompted scientists to
hypothesize that in addition to deubiquitinating substrates, ataxin-3 may facilitate their transfer
to the proteasome degradation machinery (Doss-Pepe et al., 2003). Corroborating this idea,
multiple labs reported that ataxin-3 cooperates with VCP to regulate the degradation of aberrant
proteins through the endoplasmic reticulum-associated degradation pathway (ERAD)(Arrojo et
al., 2013; Wang et al., 2006, 2008; Zhong and Pittman, 2006). However, these studies arrived at
slightly different conclusions as to how this function is carried out. It remains uncertain if
ataxin-3 is mediating substrate translocation across the ER membrane by VCP (Zhong and
Pittman, 2006), or if it is modulating the transfer of substrates from VCP to the proteasome
(Wang et al., 2006, 2008). Also unclear is if ataxin-3’s catalytic activity is involved in this
process. In terms of polyQ expansion, one study found that polyQ-expanded ataxin-3 was a
greater negative regulator of ERAD substrate degradation than its non-expanded form (Zhong
and Pittman, 2006).
In addition to the UPS, ataxin-3 may also monitor substrate degradation by autophagy.
Recently, a study reported that ataxin-3 promotes starvation-induced autophagy through polyQmediated binding to beclin-1 and subsequent stabilization via deubiquitination (Ashkenazi et al.,
2017). The authors also reported that pathogenic ataxin-3 exhibits a dominant-negative effect,
whereby it out-competes wild type ataxin-3 for binding to beclin-1, but has reduced catalytic
activity towards the protein. The result is reduced levels of beclin-1, presumably through
increased proteasomal degradation, and impaired starvation-induced autophagy in cells
(Ashkenazi et al., 2017). This seems to contradict Durcan’s previous observation that pathogenic
ataxin-3 increased degradation of parkin by autophagy (Durcan et al., 2011). It is likely that
individual autophagy substrates are affected differently by the polyQ expansion of ataxin-3.
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Nevertheless, autophagy impairment and reduced beclin-1 levels have also been reported in other
SCA3 models (Chang et al., 2016; Nascimento-Ferreira et al., 2011; Onofre et al., 2016).
Furthermore, multiple studies have reported improved phenotypes with autophagy-inducing
compounds and restoration of beclin-1 expression (Chang et al., 2016; Jia et al., 2013; Menzies
et al., 2010; Nascimento-Ferreira et al., 2013; Nascimento-Ferreira et al., 2011; Onofre et al.,
2016; Silva-Fernandes et al., 2014; Wu et al., 2017). However, this could be due to increased
clearance of aggregated ataxin-3, rather than a restoration of ataxin-3’s potential role in
autophagy.
Several lines of evidence suggest a protective role for ataxin-3 against cell stressors.
Ataxin-3 is involved in aggresome formation as a means to sequester misfolded proteins (Burnett
and Pittman, 2005; Wang et al., 2012). To accomplish this, ataxin-3 may edit the chains of
ubiquitinated substrates to signal their transport to the microtubule organizing center. This is
supported by ataxin-3’s interactions with HDAC6, dynein, and tubulin (Bonanomi et al., 2014;
Burnett and Pittman, 2005; Mazzucchelli et al., 2009; Wang et al., 2012). In response to heat
shock, ataxin-3 localizes to the nucleus (Reina et al., 2010) and upregulates transcription of
Hsp70 (Reina et al., 2012). Notably, ataxin-3 also protects against heat stress in yeast (Bonanomi
et al., 2017). When compared to their wild type counterparts, ataxin-3-knockout mouse
fibroblasts exhibit increased cell death and decreased hsp70 activation in response to heat shock
(Reina et al., 2012; Reina et al., 2010). Interestingly, pathogenic ataxin-3 still accumulates in the
nucleus and activates the hsp70 promoter upon cell stress, suggesting that it may retain some of
its protective role (Reina et al., 2012; Reina et al., 2010). However, these effects could just be a
by-product of expressing a pathogenic protein that has a propensity to misfold and aggregate in
the nucleus.

8
Upon oxidative stress, ataxin-3 translocates to the nucleus and promotes transcription of
the antioxidant enzyme, SOD2 (Araujo et al., 2011; Reina et al., 2010). To accomplish this,
ataxin-3 binds the transcription factor, FOXO4, and then they jointly bind to the SOD2 promoter.
Pathogenic ataxin-3 can bind to FOXO4 at a comparable degree to wild type ataxin-3, but it
exhibits increased binding to the SOD2 promoter (Araujo et al., 2011). Ataxin-3’s increased
binding impairs activation of SOD2 transcription, likely due to blocking FOXO4 binding to the
promoter (Araujo et al., 2011). Another study reported that ataxin-3 protects against oxidative
stress by regulating the interaction between Bcl-X(L) and Bax (Zhou et al., 2013a). Furthermore,
ataxin-3 protected against oxidative stress in a cellular model of Parkinson’s disease (Noronha et
al., 2017).
Ataxin-3 is also protective in Drosophila models of polyQ diseases, which further
supports the conclusions drawn from the cell-based experiments. Ataxin-3 reduces toxicity in fly
models of SCA1, SCA3, and HD, likely by preventing aggregation of the disease proteins (Tsou
et al., 2013; Tsou et al., 2015b; Warrick et al., 2005). However, it is unclear whether proteasome
activity is required for this process, since two independent studies arrived at opposite conclusions
(Tsou et al., 2015b; Warrick et al., 2005). Both research groups observed that ataxin-3’s DUB
activity is required for its protective function (Tsou et al., 2013; Tsou et al., 2015b; Warrick et al.,
2005). Recently, our lab reported that ataxin-3 reduces toxicity by interacting with Rad23 to
upregulate expression of the chaperone protein, DnaJ-1 (Tsou et al., 2015b). Presumably,
DnaJ-1’s refolding of misfolded polyQ proteins is responsible for their improved solubility in
these Drosophila disease models.
From the studies outlined above, ataxin-3 clearly reduces toxicity caused by
environmental stressors in cells and expanded polyQ in Drosophila. However, the significance of
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these findings has been questioned, due to contradictory results obtained from mouse models of
polyQ diseases. One study coincided with the results from cells and flies: YAC transgenic mice
with both an expanded and non-expanded allele for ataxin-3 fared better than mice with only the
expanded allele (Cemal et al., 2002). A separate research group also tested the benefit of over
expression of non-expanded ataxin-3 in their transgenic SCA3 model, but they did not observe
any phenotypic improvement (Hubener and Riess, 2010). Another study observed that knock-out
of ataxin-3 resulted in a modest increase in the motor deficiency of HD mice, but otherwise the
phenotype was unaffected (Zeng et al., 2013). Additional studies confirm that ataxin-3 knockout
mice do not exhibit any obvious adverse effects (Schmitt et al., 2007; Switonski et al., 2011). At
this point, it is unclear if ataxin-3’s neuroprotective function in flies and cells translates to
mammalian systems.
1.2.2 Transcriptional regulation
As mentioned above, ataxin-3’s cytoprotective mechanisms include transcriptional
activation of Hsp70, SOD2, and DnaJ-1. Alternatively, ataxin-3 is known to act as a
transcriptional co-repressor under non-stress conditions. This seems to be mediated, at least in
part, by modulating acetylation pathways. Ataxin-3 interacts with the histone acetyltransferases
(HATs), CREB-binding protein (CBP), p300, and p300/CBP-associated factor to inhibit their
downstream transcription (Chai et al., 2001; Li et al., 2002). In accordance with this, ataxin-3
binds histones H3/H4, and inhibits H4 acetylation by p300 (Li et al., 2002). The N-terminus of
ataxin-3 appears to be responsible for the histone-binding function, while the C-terminus
facilitates interactions with the HATs (Li et al., 2002). Ataxin-3 also recruits histone deacetylase
3 (HDAC3) to reduce both histone acetylation and transcription by the matrix
metalloproteinase-2 promoter (Evert et al., 2006). Pathogenic ataxin-3 is still capable of binding
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its interacting partners in the transcriptional pathways tested (Chai et al., 2001; Evert et al., 2006;
Li et al., 2002; Lin et al., 2014).
Overall, there is a consensus that ataxin-3’s transcriptional regulation is altered when the
polyQ is expanded, but there is conflicting evidence as to whether the transcriptional activation
or repression contributes to SCA3. For example, there are instances where pathogenic ataxin-3
loses its repressor function, and gains an activating function (Chai et al., 2001; Evert et al.,
2006). Conversely, there are studies reporting that pathogenic ataxin-3 represses transcription,
and alleviating this improves the phenotype in SCA3 mouse models (Chou et al., 2011a; Chou et
al., 2014). In some cases, pathogenic ataxin-3 increases histone acetylation (Evert et al., 2006),
but it decreases acetylation in others (Lin et al., 2014). Increasing acetylation levels with HDAC
inhibitors often improves the phenotype in SCA3 mouse and Drosophila models (Chou et al.,
2011a; Chou et al., 2014; Lin et al., 2014; Wang et al., 2018; Yi et al., 2013), but not always
(Esteves et al., 2015). Most likely, it varies based on the gene whether a loss or gain of
transcriptional repression contributes to SCA3 toxicity. The different disease models in use
could also be contributing to the variability in results. Interestingly, ataxin-3’s function as a
transcriptional repressor may also be relevant in cancer, since it reportedly inhibits transcription
of the tumor suppressor, PTEN (Sacco et al., 2014).
1.2.3 DNA repair
In the past few years, researchers have published exciting findings that identify a novel
role for ataxin-3 in DNA repair pathways. For example, ataxin-3 interacts with polynucleotide
kinase 3’-phosphatase (PNKP), a DNA repair enzyme involved in single-strand break repair and
non-homologous end joining (Chatterjee et al., 2015; Gao et al., 2015). Ataxin-3 stimulates
PNKP’s phosphatase activity so it can signal DNA repair pathways (Chatterjee et al., 2015; Gao
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Figure 1.1. The physiological functions of ataxin-3. Ataxin-3 has multiple proteininteracting domains that are essential for performing its functions in protein quality control,
transcription, and DNA repair. There is cross-talk between some of these pathways.
et al., 2015). On the other hand, pathogenic ataxin-3 inhibits PNKP’s phosphatase activity,
increases DNA damage, activates the ATM-mediated damage-response pathway, and triggers
p53-dependent apoptosis in cells and SCA3 transgenic mice (Chatterjee et al., 2015; Gao et al.,
2015). These findings are in agreement with a role for ataxin-3 in regulation of p53’s stability
and subsequent transcription of apoptotic genes (Liu et al., 2016). Furthermore, an increase in
DNA damage was observed in SCA3 patient brain tissue (Chatterjee et al., 2015; Gao et al.,
2015).
Complimentary to these findings, a study using C. elegans reported that ataxin-3 localizes
to double-stranded break-associated foci, which contain CDC-48(VCP), proteasomes, and the E4
ligase, Ufd-2 (Ackermann et al., 2016). These foci are associated with an increase in DNA
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damage-dependent apoptosis. However, the presence of ataxin-3 seems to oppose the formation
of these foci, since ataxin-3 mutants exhibit increased formation of foci and apoptotic signaling
(Ackermann et al., 2016). These findings raise the possibility that ataxin-3’s function in the UPS
could also overlap with its regulation of DNA repair pathways.
Supporting this idea, the ubiquitination of Chk1 and MDC1, two DNA damage
checkpoint mediators, were found to be regulated by ataxin-3 (Pfeiffer et al., 2017; Tu et al.,
2017). In response to DNA damage, ataxin-3 deubiquitinates Chk1 to prevent its proteasomal
degradation (Tu et al., 2017). This allows Chk1 to activate the G2/M DNA damage checkpoint
and signal for DNA repair mechanisms (Tu et al., 2017). After prolonged DNA stress, ataxin-3
dissociates from Chk1 so it can be degraded, thus resuming the cell cycle. The polyQ-expanded
form of ataxin-3 still interacts with and stabilizes Chk1 (Tu et al., 2017). Alternatively, ataxin-3
was also found to localize to sites of DNA damage in a sumoylation-dependent manner (Nishi et
al., 2014; Pfeiffer et al., 2017). Importantly, other labs have also gathered evidence for
sumoylation of ataxin-3 (Almeida et al., 2015; Guzzo and Matunis, 2013; Shen et al., 2005; Zhou
et al., 2013b). Once recruited to the DNA, ataxin-3 counteracts the sumo-targeted Ub ligase,
RNF4, to reduce the ubiquitination of MDC1 (Pfeiffer et al., 2017). This is presumably through
deubiquitination, since ataxin-3’s catalytic activity is required for this effect. In this manner,
ataxin-3 increases MDC1’s interaction with the DNA and the MDC1-mediated recruitment of
other DNA repair proteins (Pfeiffer et al., 2017).
Further supporting these collective findings, loss of ataxin-3 compromises the Chk1-,
MDC1-, and PNKP-mediated DNA damage response pathways and sensitizes cells to DNAdamaging agents (Chatterjee et al., 2015; Pfeiffer et al., 2017; Tu et al., 2017). Altogether, these
studies demonstrate that ataxin-3 is involved in multiple major DNA repair pathways. Future
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work will enhance our understanding of this physiological function of ataxin-3 and how it plays
into SCA3.
1.3 Protein context in polyglutamine disorders
Despite the shared mutation in the polyQ tract, each polyQ disorder presents with a
distinct set of symptoms and degenerated brain regions (Matos et al., 2011). This selective
degeneration is very intriguing, since most of these disease proteins are widely expressed, and
many are expressed in the same cell types (Costa Mdo and Paulson, 2012). Furthermore, each
disorder has its own threshold for when the polyQ expansion of the disease protein switches
from normal to toxic (La Spada and Taylor, 2003). Humans also possess genes encoding polyQ
proteins that do not cause disease (Schaefer et al., 2012), leaving scientists to wonder what is so
significant about the polyQ proteins that cause this class of neurodegenerative diseases.
For these reasons, the protein context, meaning the normal physiological functions and
non-polyQ domains of the disease proteins, are thought to play a major role in pathogenesis (La
Spada and Taylor, 2003; Orr, 2012; Robertson and Bottomley, 2010). For example, non-polyQ
domains surrounding the polyQ tract, including their post-translational modifications, can
influence the aggregation and toxicity of the full-length protein (Adegbuyiro et al., 2017; La
Spada and Taylor, 2003; Orr, 2012; Pennuto et al., 2009; Robertson and Bottomley, 2010;
Saunders and Bottomley, 2009). Protein-interacting domains that are required for a nonexpanded polyQ protein’s function can provide clues for toxic mechanisms that occur when the
polyQ tract becomes expanded (La Spada and Taylor, 2003; Orr, 2012; Saudou and Humbert,
2016). In some cases, the presence or absence of non-polyQ domains in the full-length protein
can determine whether disease pathogenesis occurs, or not (Klement et al., 1998; Tsuda et al.,
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2005). This section will highlight the most striking evidence for a link between protein context
and polyQ disease pathogenesis.
1.3.1 Huntington’s disease (HD)
HD is the most common polyQ disorder, so naturally, it is the most studied. There is a
wealth of information supporting protein context in HD. Many post-translational modifications
influence huntingtin (htt) toxicity, including phosphorylation (Schilling et al., 2006), acetylation
(Jeong et al., 2009), ubiquitination (Jana et al., 2005), sumoylation (Steffan et al., 2004) and
caspase cleavage (Graham et al., 2006). Additionally, several protein-interaction pathways may
influence HD disease mechanisms (Saudou and Humbert, 2016). Unfortunately, it is unfeasible
to adequately address all of the studies on HD protein context in this chapter. Instead, this section
will focus on two domains immediately adjacent to the polyQ tract that influence huntingtin (htt)
aggregation and toxicity.
Regions flanking the polyQ domain of htt have been found to alter its aggregation
propensity. Notably, the first 17 amino acids of htt (N17), located upstream of the polyQ tract,
promote its aggregation in vitro (Adegbuyiro et al., 2017; Hoffner and Djian, 2014). This is
believed to occur through stimulation of htt self-association, since N17 can bind to other N17
domains, as well as the polyQ tract (Hoffner and Djian, 2014; Tam et al., 2009; Thakur et al.,
2009). Blocking N17 can reduce aggregation of pathogenic Htt-exon1, as evidenced by binding
of the chaperone, TriC, in mammalian cells (Tam et al., 2009). N17 of full-length htt can be posttranslationally modified by phosphorylation at serines 13 and 16 (Gu et al., 2009). The
significance of this modification has been confirmed in vivo; mutation of these residues to alanine
prevents motor, behavioral, neurodegenerative, and aggregation phenotypes in BAC transgenic
mice expressing full-length, mutant htt (Gu et al., 2009).
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Alternatively, the polyproline region (polyP) of htt, located at the C-terminus of the
polyQ tract, reduces the aggregation propensity of the HD protein. When polyP is added onto the
C-terminus of a pure polyQ tract, the conformation of the polyQ is altered and its aggregation
rate is decreased in vitro (Bhattacharyya et al., 2006; Thakur et al., 2009). By preventing the
polyQ from adopting a β-sheet conformation, polyP protects against htt aggregation (Darnell et
al., 2007; Lakhani et al., 2010). In yeast cells, deletion of the proline-rich domain leads to
increased aggregation and toxicity of polyQ-expanded htt-exon1 (Dehay and Bertolotti, 2006;
Duennwald et al., 2006). Intriguingly, the effects of the polyP domain are position-specific, since
addition of polyP to the N-terminus of the polyQ tract does not influence aggregation
(Bhattacharyya et al., 2006; Thakur et al., 2009). It is worth noting that the polyP domain is also
a site of many protein interactions that could potentially influence HD pathogenesis (Khoshnan
et al., 2004; Passani et al., 2000; Steffan et al., 2000).
One shortfall for many HD studies, including several of the publications mentioned here,
is that they use a truncated form of the htt protein, containing only exon 1. This is because the htt
protein is very large (67 exons; ncbi.nlm.nih.gov/gene/3064), and the polyQ domain is located
within the first exon. Ideally, future work should confirm the influence of htt's non-polyQ
domains on htt aggregation with the full-length protein in cell-based and in vivo systems.
1.3.2 Spinocerebellar ataxia type 1 (SCA1)
Protein context in SCA1 has been firmly established by work conducted in the Zoghbi
and Orr labs. Nearly 2 decades ago, they discovered that ataxin-1’s nuclear localization signal is
essential for pathogenesis in SCA1 mice (Klement et al., 1998). Several years later, they
observed that ataxin-1 is phosphorylated at serine 776, and mutating this serine to alanine
substantially reduces toxicity in SCA1 transgenic mice (Emamian et al., 2003). This

16
phosphorylated residue was also found to be required for its interaction with the 14-3-3 protein
(Chen et al., 2003). The same study reported that 14-3-3 binding to ataxin-1 enhances
polyglutamine toxicity in a Drosophila model of SCA1, by slowing degradation of ataxin-1
(Chen et al., 2003). Phosphorylation of serine 776 is also critical for ataxin-1’s interaction with
the splicing factor, RBM17, and this interaction is promoted by increasing polyQ tract length
(Lim et al., 2008). Interestingly, modulating levels of RBM17 influences ataxin-1 toxicity in
Drosophila; overexpression enhances toxicity, while loss of one RBM17 allele suppresses
toxicity (Lim et al., 2008).
The AXH domain of ataxin-1 also influences the SCA1 protein’s properties. This domain
is the binding site for many of ataxin-1’s interactions with other proteins, including its own selfassociation, and is at least partially responsible for ataxin-1’s function as a transcriptional
repressor (Chen et al., 2004; de Chiara et al., 2003; de Chiara et al., 2005). Studies conducted by
the Orr and Zoghbi labs demonstrated that the AXH domain of ataxin-1 directly binds to the
Drosophila transcription factor, Senseless, and its mammalian homologue, Gfi-1 (Tsuda et al.,
2005). Ataxin-1 negatively regulates the expression levels of Senseless/Gfi-1, but deletion of the
AXH domain increases the transcription factor’s stability and reduces overall polyQ toxicity (de
Chiara et al., 2005; Tsuda et al., 2005). Alternatively, the AXH domain is also the site of
ataxin-1’s interaction with Capicua, a transcriptional repressor that modulates toxicity in SCA1
(Fryer et al., 2011; Lam et al., 2006). Ongoing research continues to elucidate the mechanisms
and outcomes of the Capicua-AXH interaction in this disease (Lu et al., 2017).
1.3.3 Spinal and bulbar muscular atrophy (SBMA)
Protein context also plays a role in SBMA, the only X-linked, recessive polyQ disorder
(Costa Mdo and Paulson, 2012). The expanded protein in this case is the androgen receptor
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(AR), whose nuclear receptor domains are required for disease progression. For instance, the
nuclear localization signal, as well as the ligand-binding domain that binds testosterone, are
required for pathogenesis in fly and mouse models of SBMA (Montie and Merry, 2009;
Takeyama et al., 2002). Additionally, experiments conducted in Drosophila show that the AR’s
DNA-binding domain and AF-2 interacting domain are also required for toxicity (Nedelsky et
al., 2010). Furthermore, altering the levels of testosterone modulates toxicity of AR in vivo
(Katsuno et al., 2002; Takeyama et al., 2002).
Conversely, a leucine-rich region immediately preceding the AR's polyQ tract may work
to prevent toxicity in SBMA; this leucine-rich domain reduces aggregation of an N-terminal AR
fragment in vitro by maintaining the alpha-helical conformation of the polyQ tract
(Eftekharzadeh et al., 2016). On the other hand, another sequence in AR’s N-terminus, located
downstream of the polyQ tract, appears to enhance AR fibrilization (Oppong et al., 2017). The
significance of these domains has not been tested with a full-length AR protein in an in vivo
setting, but such studies could provide valuable insight into aggregation mechanisms in SBMA.
1.3.4 Spinocerebellar ataxia type 3 (SCA3)
The catalytic Josephin domain of ataxin-3 is known to promote aggregation of the SCA3
protein. Both wild type and mutant ataxin-3 form SDS-soluble aggregates in vitro (Chow et al.,
2004; Ellisdon et al., 2006; Gales et al., 2005; Masino et al., 2004) and are present in nuclear
inclusions in vivo (Fujigasaki et al., 2000; Fujigasaki et al., 2001; Lieberman et al., 1999),
suggesting that this process can occur independently of an expanded polyQ tract. However, only
ataxin-3 with expanded polyQ can form SDS-insoluble aggregates (Ellisdon et al., 2006;
Natalello et al., 2011). Notably, aggregation of isolated Josephin occurs in a manner very similar
to full-length, non-expanded ataxin-3, where its conformation transitions from an alpha-helix to a
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beta-sheet (Ellisdon et al., 2006; Masino et al., 2011; Masino et al., 2004; Natalello et al., 2011).
Together, these findings have led to the hypothesis that ataxin-3 aggregation occurs through a
two-step mechanism in which aggregation is first initiated by the Josephin domain and then
propagated by the polyQ expansion (Ellisdon et al., 2006; Scarff et al., 2015; Silva et al., 2017).
Post-translational modifications to ataxin-3 also appear to influence its aggregation and
toxicity. Sumoylation at lysine 356 reduces ataxin-3 aggregation in vitro and in rat cortical
neurons (Almeida et al., 2015). Intriguingly, this modification also enhances ataxin-3’s
interaction with the AAA ATPase, VCP/p97 (Almeida et al., 2015), which will be discussed
further in Chapter 4. GSK3β phosphorylates ataxin-3 on serine 256, and ataxin-3’s aggregation is
increased in mammalian cells when this site is mutated to a non-phosphorylatable alanine (Fei et
al., 2007). This is an interesting finding, since the authors also observed that GSK3β
phosphorylates pathogenic ataxin-3 less than the non-pathogenic form (Fei et al., 2007).
Additionally, phosphorylation of ataxin-3 at serine 12 by an unidentified kinase was shown to
reduce ataxin-3 aggregation in cortical neurons and prevent neuronal loss in a lentiviral rat model
of SCA3 (Matos et al., 2016). Moreover, phosphorylation at serine residues 29 (Josephin
domain), 340 (UIM3), and 352 (UIM3) increase ataxin-3’s nuclear localization (Mueller et al.,
2009; Pastori et al., 2010), which is a critical determinant of SCA3 pathogenesis (Bichelmeier et
al., 2007; Paulson et al., 1997b). Altogether, these studies indicate that post-translational
modifications have the potential to accelerate or attenuate SCA3 progression.
1.4 Conclusions
Although the polyQ disorders have unifying features, it is their mutated proteins that
make each disease unique. Each polyQ protein has their own set of physiological functions that
can go awry to cause disease. Research into ataxin-3’s roles in protein quality control,
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transcriptional regulation, and DNA repair elucidates several pathways that are altered in SCA3.
Interestingly, some of these functions seem to overlap: transcriptional regulation contributes to
protection against cell stress, DUB activities facilitate DNA repair and transcription, etc (Figure
1.1). Furthermore, identification of the structural domains that are required for these functions
opens the door to the development of targeted therapeutics. Future efforts to merge our
understanding of sequence domains and post-translational modifications that modulate toxicity
with the normal physiological functions of ataxin-3 will enhance our understanding of SCA3 and
how to treat it.
Alternatively, while protein context makes the diseases unique, it is evident that there are
some shared mechanisms. Ataxin-3, ataxin-1, htt, AR, each exhibit increased toxicity when
localized to the nucleus. All of the proteins have at least one domain that tends to self-associate
and promote aggregation. The ability of post-translational modifications to influence polyQ
protein aggregation and toxicity is also a unifying feature. Therefore, new discoveries about
protein context in one polyQ disorder have the potential to enhance our understanding of the
disease class as a whole.
For all of these reasons, my thesis explores the interactions between ataxin-3 and two of
its protein-binding partners: Rad23 and VCP. These studies demonstrate that Rad23 and VCP can
modulate the toxic properties of ataxin-3 in vivo, thus providing novel information about protein
context in SCA3.
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CHAPTER 2: Materials and Methods
Adapted from:
Published: Sutton JR, Blount JR, Libohova K, Tsou W-L, Joshi GS, Paulson HL, Costa MDC,
Scaglione KM, Todi SV (2017). Interaction of the polyglutamine protein ataxin-3 with Rad23
regulates toxicity in Drosophila models of Spinocerebellar Ataxia Type 3. Human Molecular
Genetics 26, 1419-1431.
Under review: Ristic GR*, Sutton JR*, Libohova K, Todi SV (2018). Toxicity and aggregation
of the polyglutamine disease protein, ataxin-3 is regulated by its binding to VCP/p97 in
Drosophila melanogaster. Neurobiology of Disease. *- these authors contributed equally to this
manuscript.
Antibodies: Anti-Ataxin-3 (mouse monoclonal 1H9, 1:500-1,000; Millipore) (rabbit polyclonal, 1:15,000; (Paulson et al., 1997a)); anti-VCP (rabbit monoclonal, 1:1,000; Cell Signaling
Technology); anti-tubulin (mouse monoclonal T5168, 1:10,000; Sigma-Aldrich); anti-HIS (rabbit
monoclonal 1:1,000; Cell Signaling); anti-HA (rabbit monoclonal, 1:500-1,000; Cell Signaling
Technology); anti-GAPDH (mouse monoclonal MAB374, 1:500; Millipore); anti-lamin (mouse
monoclonal ADL84.12-5, 1:1,000; Developmental Studies Hybridoma Bank); peroxidaseconjugated secondary antibodies (goat anti-rabbit and goat anti-mouse, 1:5,000; Jackson
Immunoresearch).
Drosophila lines: Husbandry was conducted at 25°C on standard cornmeal food at 40%-60%
humidity in a regulated diurnal environment. SCA3 flies expressing pathogenic ataxin-3 with
77-80 polyQ repeats were generated by cloning into the pWalium10-moe vector (Perrimon lab).
“HNHH”, “UbS2*Mild”, and “UbS2*Severe” mutations were generated on the pathogenic ataxin-3
backbone using the QuikChange mutagenesis kit (Agilent), then cloned into the pWalium10-moe
vector. Rad23-overexpressing flies were generated by using HIS6-tagged Drosophila Rad23
cloned into the pWalium10-moe vector. Injections (Duke University Model Systems) were into y,
w; +; attP2. The following stocks from purchased from the Bloomington Drosophila Stock
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Center: isogenic host strain for GMR-Gal4 (#8121), attP2 (#36303), DnaJ-1 RNAi (#32899),
VCP RNAi lines (#32869, #35608), UAS-DnaJ-1 (#30553), and UAS-polyQ78 (#8141). Rad23
RNAi (#30498) and its isogenic line (#60000) were purchased from the Vienna Drosophila
RNAi Center. The following lines were gifts: sqh-Gal4 driver (Dr. Daniel P. Kiehart, Duke
University), elav- Gal4(GS) driver (Dr. Robert Wessells, Wayne State University), elav-Gal4
driver (Dr. Daniel F. Eberl, University of Iowa).
Longevity assay: Upon eclosion, approximately 25 male and female adults were collected and
aged in conventional cornmeal fly media or RU-486-containing media (Nicholson et al., 2008;
Osterwalder et al., 2001; Roman and Davis, 2002; Sujkowski et al., 2015) at 25°C. Flies were
transferred to vials with fresh food every 2–3 days. Each vial was checked for death daily, until
all flies were dead. Longevity comparisons were restricted to fly lines in the same genetic
background, since flies from different backgrounds can have different lifespans (Paaby and
Schmidt, 2009; Spencer et al., 2003).
Motility Assay (Negative Geotaxis): Approximately 10 adult flies per vial were forced to the
bottom by tapping on the bench. The number of flies that reached the top at 5, 15 and 30 seconds
was recorded. The assay was conducted once a week for 4 weeks. Flies were transferred to new
vials 1 hour before the assay was conducted, and every 2–3 days for the duration of the
experiment.
Ataxin-3 Pulse-Chases in Drosophila: Fly crosses were set up in standard cornmeal media
under the conditions described in “Drosophila lines”. After eclosion, adult offspring possessing
transgenes for the inducible elav-Gal4(GS) driver and UAS-Ataxin-3(SCA3)-Intact or UASAtaxin-3(SCA3)-HNHH were transferred to cornmeal media containing RU-486 (Nicholson et
al., 2008; Osterwalder et al., 2001; Roman and Davis, 2002; Sujkowski et al., 2015). Expression
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of UAS-Ataxin-3(SCA3)-Intact was induced in the RU-486-containing media for 7 or 14 days;
expression of UAS-Ataxin-3(SCA3)-HNHH was induced for 10 or 21 days. At the end of the
induction period, flies were transferred back to the standard cornmeal media for the chase period.
Flies were collected for western blot analysis at day 0, 1,7, 14, and 21 of the chase period.
Motility and western blot analysis were carried out as described above.
Histology: Wings and proboscises were removed from male, adult flies and bodies were fixed
overnight in 2% glutaraldehyde/2% paraformaldehyde in Tris-buffered saline with 0.1% Triton
X-100. Fixed adults were then dehydrated in a series of 30, 50, 75, and 100% ethanol washes for
1 hour each, then washed in propylene oxide overnight. Dehydrated flies were embedded in Poly/
Bed812 (Polysciences) and sectioned at 5 µm. Sections were stained with toluidine blue.
Western blotting: Three to 5 whole flies, 10 to 15 dissected fly heads, or 10 larvae per group
were homogenized in hot lysis buffer (50 mM Tris pH 6.8, 2% SDS, 10% glycerol, 100mM
dithiothreitol), sonicated, boiled for 10 minutes, and centrifuged at top speed at room
temperature for 10 min. Samples were electrophoresed on 4-20% gradient gels (BioRad).
Western blots were developed and quantified using a CCD-equipped VersaDoc 5000MP system
and Quantity One software (Bio-Rad). For direct blue staining, PVDF membranes were
submerged for 5 minutes in 0.1% Direct Blue 71 (Sigma-Aldrich) stock solution in ultra pure
water, dissolved in 40% ethanol and 10% acetic acid solvent. Membrane was rinsed briefly in
solvent, then ultra pure water, air dried, and imaged.
Differential Centrifugation: Five whole flies per group were lysed in 200 μl of NETN buffer
(50 mM Tris, pH 7.5, 150 mM NaCl, 0.5% Nonidet P-40), supplemented with protease inhibitor
cocktail (PI, SigmaFast Protease Inhibitor Cocktail Tablets), sonicated, and centrifuged at 20,000
x g for 30 minutes at 4 ̊C. The supernatant was transferred to a new tube and quantified by the
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BCA assay. The pellet was resuspended in 200 μl of PBS + 1% SDS, vortexed, and boiled. Ten
μg of the supernatant fraction and 7 μl of the pellet fraction were supplemented with 6x SDS,
boiled, and loaded onto 4-20% gradient gels for western blot analysis.
Nuclear Cytoplasmic Extraction: Experiments were conducted using the ReadyPrep Protein
Extraction Kit ((Cytoplasmic/Nuclear), BioRad) to enrich cytoplasmic and nuclear proteins. Five
whole adult flies were lysed in cytoplasmic extraction buffer (Bio- Rad). Nuclei were
resuspended in Protein Solubilization Buffer (BioRad). Samples were analyzed by western blot.
Quantitative RT-PCR: Total RNA was extracted from larvae or adult flies using TRIzol (Life
Technologies). Extracted RNA was treated with TURBO DNAse (Ambion) to eliminate
contaminating DNA. Reverse transcription was carried out with the high-capacity cDNA reverse
transcription kit (ABI). Messenger RNA levels were quantified by using the StepOnePlus RealTime PCR System with Fast SYBR Green Master Mix (ABI). rp49 was used as an internal
control. Primers:
SCA3 - F: 5’ GAATGGCAGAAGGAGGAGTTACTA - 3’
SCA3 - R: 5’ GACCCGTCAAGAGAGAATTCAAGT - 3’
rp49-F: 5’ -AGATCGTGAAGAAGCGCACCAAG- 3’
rp49-R: 5’ -CACCAGGAACTTCTTGAATCCGG- 3’
Cell lines, plasmids, transfection & chemicals: HeLa and HEK293 cells were purchased from
ATCC and cultured in DMEM supplemented with 10% FBS and 5% Penicillin-Streptomycin
under conventional conditions. The day before transfection, cells were seeded in 6- or 12-well
plates. Cells were transfected using Lipofectamine LTX (Invitrogen) as directed by the
manufacturer. Twenty-four hours after transfection, cells in 12-well plates were lysed in boiling
SDS lysis buffer for western blot analysis. Cells in 6-well plates were harvested in PBS, pelleted
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by centrifugation at 500 x g for 5 minutes at 4°C, and frozen at -80°C for immunoprecipitation
experiments. Non-pathogenic ataxin-3 constructs were in pcDNA3.1-HA. Pathogenic ataxin-3
constructs were in pFLAG-CMV6a. VCP construct was in pEGFP. Cycloheximide (A.G.
Scientific) dissolved in ultra-pure water, was used at 50 mg/ml.
Co-Immunoprecipitation: For co-IPs from fly lysates, 30-50 fly heads per group were
homogenized through mechanical disruption in PBS + PI, briefly sonicated, and then
supplemented with the equal volume of NETN + PI. Lysates were vortexed briefly every 5
minutes for a total of 30 minutes, centrifuged at 5,000 x g for 5 minutes at 4̊C, and supernatant
was transferred to 30 μl slurry of anti-HA bead-bound antibody (Sigma- Aldrich). Beads with
lysates were tumbled at 4 ̊C for 4 hours. For co-IPs from cell lysates, HEK293 or HeLa cells
were transfected and harvested as described under “Cell Lines, Plasmids, and Transfections”.
Cell pellets were lysed in 500 mL of NETN+PI, vortexed briefly every 5 minutes for a total of 30
minutes, and centrifuged at 12,000 x g for 15 minutes at 4̊C. Supernatants were transferred to 30
μl slurry of anti-FLAG bead-bound antibody (Sigma-Aldrich). Beads with lysates were tumbled
at 4 ̊C for 4 hours. For in vitro pulldowns, 1.5 mL of bacterial lysate containing GST, GSTAtaxin-3(SCA3)-Intact, or GST-Ataxin-3(SCA3)-HNHH was tumbled with 20 μl of glutathione
sepharose slurry for 30 minutes. Both Ataxin-3(SCA3) constructs contained 80 polyQ repeats.
GST-Atax- in-3(SCA3)-Intact and Ataxin3(SCA3)-HNHH supernatants were replaced with 1.5
mL of fresh bacterial lysate before tumbling all lysates for an additional 30 minutes. Forty whole
flies were homogenized in 500 μl of NETN + PI, sonicated, and centrifuged at 15,000 x g for 15
minutes at 4̊C. The bacterial lysate was removed from the beads, beads were rinsed with NETN
+ PI, the fly lysate was distributed evenly among the 3 experimental groups, and samples were
tumbled for 2 hours at 4 ̊C. Bead-bound complexes from all co-immunoprecipitations were
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rinsed thrice with NETN + PI, then eluted with heat and Laemmli buffer.
Protein Purification: Glycerol stocks of BL21 cells transformed with pGEX6p1, pGEX6p1Ataxin-3(SCA3)-Intact, or pGEX6p1-Ataxin-3(SCA3)-HNHH were used to inoculate 10 mL of
LB + 50 ug/mL ampicillin. Both Ataxin-3(SCA3) constructs contained 80 polyQ repeats.
Cultures were grown overnight at 37̊C, then used to inoculate 500 mL of LB + ampicillin, which
was grown for an additional 1.5 hours to OD600=.60. Protein expression was induced with 0.5
mM of isopropyl-1-β-D-galactopyranoside (A. G. Scientific) for 4h at 30 °C. Bacterial cells were
pelleted by centrifugation at 4,500 x g for 10 minutes at 4°C. Pellets were lysed in NETN buffer,
sonicated, centrifuged, aliquoted, and frozen at -80°C.

26
CHAPTER 3: Interaction of the polyglutamine protein, ataxin-3, with Rad23 regulates
toxicity in Drosophila models of Spinocerebellar ataxia type 3
Published: Sutton JR, Blount JR, Libohova K, Tsou W-L, Joshi GS, Paulson HL, Costa MDC,
Scaglione KM, Todi SV (2017). Interaction of the polyglutamine protein ataxin-3 with Rad23
regulates toxicity in Drosophila models of Spinocerebellar ataxia type 3. Human Molecular
Genetics 26, 1419-1431.
3.1 Introduction
Polyglutamine (polyQ)-dependent diseases comprise a class of neurodegenerative
disorders characterized by abnormal CAG nucleotide repeat expansions in the disease gene
(Costa Mdo and Paulson, 2012). These repeats translate into an abnormally long polyQ tract,
resulting in subsequent misfolding and aggregation of the disease protein in neurons and,
ultimately, neuronal dysfunction and death. Among these disorders, Spinocerebellar Ataxia Type
3 (SCA3, or Machado-Joseph Disease), is the most common dominantly inherited ataxia in the
world (Costa Mdo and Paulson, 2012; Matos et al., 2011). Onset occurs in mid to late life, with
degeneration observed in cerebellar pathways and nuclei, dentate nuclei, pontine nuclei, and
basal ganglia. Symptoms include ataxia, dysarthria, dystonia, ophthalmoplegia, spasticity, and
neuropathy (Costa Mdo and Paulson, 2012). There is no cure for SCA3.
SCA3 is caused by expansion of a CAG tract in ATXN3 from 22–42 repeats to a disease
range of 52–84, leading to the translation of a pathogenic form of the ataxin-3 protein with
expanded polyQ (Costa Mdo and Paulson, 2012; Matos et al., 2011). Ataxin-3, a deubiquitinating
enzyme, edits ubiquitin chains on substrates (Scaglione et al., 2011; Winborn et al., 2008); it has
been reported to function in protein quality control and transcriptional regulation (Costa Mdo
and Paulson, 2012; Reina et al., 2012; Sacco et al., 2014; Scaglione et al., 2011; Todi et al.,
2010), and is neuroprotective in Drosophila melanogaster, where it suppresses degeneration
from various polyQ proteins (Burr et al., 2014; Tsou et al., 2013; Tsou et al., 2015b; Warrick et
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al., 2005). Ataxin-3 also protects against various stressors in mammalian cell culture (Chatterjee
et al., 2015; Reina et al., 2012; Reina et al., 2010; Zhou et al., 2013a).
The N-terminal catalytic domain of ataxin-3 contains two ubiquitin-binding sites that can
bind mono-ubiquitin (Nicastro et al., 2009; Nicastro et al., 2010) Ubiquitin-binding site 2 (UbS2)
also binds to the proteasomal shuttle proteins, Rad23/hHR23A and B (Nicastro et al., 2009;
Nicastro et al., 2005; Nicastro et al., 2010; Wang et al., 2000). According to our earlier published
work, proteasomal degradation of ataxin-3 is regulated by the direct interaction between UbS2
and Rad23 (Blount et al., 2014). When Rad23 is bound to UbS2, ataxin-3 is protected from
degradation (Figure 3.1A). Disrupting this interaction decreases the steady state levels of
ataxin-3 in the cell. While this previous work showcased the importance of the ataxin-3-Rad23
interaction for the SCA3 protein’s turnover, it did not directly test whether this interaction is
critical for ataxin-3-dependent toxicity. In other words, does UbS2 of ataxin-3 directly modulate
SCA3 pathogenicity? More importantly, should UbS2 be targeted to protect against SCA3, since
it regulates overall cellular levels of ataxin-3?
Here, we show that disrupting UbS2 of disease-causing ataxin-3 decreases the levels of
the pathogenic ataxin-3 protein, but greatly enhances its toxicity in vivo. Further investigations
indicate that this increase in toxicity is due to a reduction in ataxin-3’s neuroprotective function
against itself, which is mediated by the UbS2-Rad23 interaction and depends on the chaperone
partner, DnaJ-1. Our data demonstrate a critical role for the interaction of ataxin-3 with Rad23 in
the regulation of this polyQ protein’s abundance, function, and pathogenicity.
3.2 Results
3.2.1 Modulating levels of Rad23 influences ataxin-3’s toxicity in Drosophila
To examine the function of the interaction between UbS2 of ataxin-3 and Rad23, we used
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a transgenic fly model of SCA3 that we recently generated by using the phiC31-targeted
integration system (Groth et al., 2004). The phiC31 system yields a similar expression of
transgenes among different fly lines, due to site-specific integration (Groth et al., 2004), in our
case into attP2 on the third chromosome of the fly. This method allows for direct comparisons
among the different transgenic lines we generated (Figure 3.1B). Our Drosophila model of
SCA3 expresses untagged, full-length, human pathogenic ataxin-3 under the control of the Gal4/
UAS system. We also generated a control line that contains the empty host vector inserted into
attP2 (Tsou et al., 2015a) and another line that expresses wild-type, human ataxin-3, inserted at a
different site than attP2 (Tsou et al., 2013).
When pathogenic ataxin-3 (Ataxin-3(SCA3)) is expressed throughout the fly, it leads to
some lethality at late pharate adult stages and during eclosion from the pupal case (Figure 3.1C).
Those flies that mature into adulthood only live up to 30 days, as opposed to the control flies that
live up to 100 days (Figure 3.1D).
Previously, we reported that reducing the levels of endogenous Rad23 through RNAi by
approximately 50%, as determined through qRT-PCR, or by removing one copy of its gene,
decreased ataxin-3 protein levels and noticeably improved degeneration in Drosophila eyes
expressing pathogenic ataxin-3 with an intact UbS2 ((Blount et al., 2014); other supporting data
not shown). We recapitulated this effect by reducing endogenous Rad23 levels in all the tissues
of the fly through RNAi. We observed improved adult longevity compared to sibling SCA3 flies
without Rad23 knockdown (Figure 3.1E). Based on our earlier work with various Gal4 drivers
and different polyQ and non-polyQ constructs (Blount et al., 2014; Ristic et al., 2016; Tsou et al.,
2013; Tsou et al., 2015a; Tsou et al., 2015b), improved longevity from pathogenic ataxin-3 when
Rad23 is knocked down through UAS-RNAi is not due to a dilution effect of the Gal4 driver co-
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Figure 3.1. Rad23 influences Ataxin-3(SCA3)-dependent toxicity. (A) Model depicting how Rad23 influences ataxin-3’s degradation,
based on studies from Blount et al., 2014. The ubiquitin-interacting motifs (UIMs) of ataxin-3 bind ubiquitin chains on proteasome
substrates, facilitating the interaction of ataxin-3 with this machinery. Once at the proteasome, in the absence of interaction with Rad23,
ataxin-3 is degraded. If ataxin-3 interacts with Rad23 through UbS2, it is rescued. (B) Summary of transgenic Drosophila lines used. (C)
Observations with ubiquitous expression of pathogenic ataxin-3 with or without Rad23 overexpression. In this panel and rest of the figures,
unless otherwise noted, flies were heterozygous for all transgenes. (D) Longevity of flies ubiquitously expressing pathogenic ataxin-3 or the
empty host vector inserted into attP2. (E) Longevity of flies ubiquitously expressing pathogenic ataxin-3 without or with UAS-RNAi
targeting Rad23. A control line was included that expresses Rad23 RNAi in the absence of ataxin-3. Flies were siblings from the same
crosses and on a different background (y-w-) than flies in the rest of this figure (w1118). (F) Western blots from independent lysates of whole
flies ubiquitously expressing the specified transgenes. Means ± SD. Asterisks: P< 0.05 from Student’s t-tests compared to UASAtaxin-3(SCA3) without exogenous Rad23. When quantifying ataxin-3 protein levels for (-)Rad23 flies, lane 4 was set to 100%. Lane 5 was
not quantified, due to the bubble disrupting the ataxin-3 band. (G) Longevity of flies ubiquitously expressing pathogenic ataxin-3 with or
without Rad23 overexpression.
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expressing ataxin-3 and the knockdown construct.
Conversely

to

Rad23

knockdown,

exogenous

Rad23

noticeably

increases

Ataxin-3(SCA3) protein levels (Figure 3.1F). This increase in protein levels coincides with
higher lethality (Figure 3.1C). Almost all of the SCA3 flies that co-express Rad23 die as pharate
adults, before they eclose from the pupal case. Very few adult flies co-expressing Rad23 and
Ataxin-3(SCA3) eclose successfully (Figure 3.1C). Those flies that survive to adulthood exhibit
reduced longevity compared to the SCA3 flies that are not expressing exogenous Rad23 (Figure
3.1G).
Flies expressing exogenous Rad23 or expressing RNAi targeting Rad23 in the absence of
ataxin-3 were kept as healthy stocks for over a year without clear signs of reduced fecundity or
of toxicity (Figure 3.1E and data not shown). These collective data from the perturbation of
Rad23 levels support the idea that this proteasome-associated protein regulates pathogenic
ataxin-3 levels and subsequent toxicity. These results led us to next investigate if disturbing the
binding site of this protein on ataxin- 3 is beneficial in vivo.
3.2.2 Mutating UbS2 reduces ataxin-3 protein levels, but greatly enhances its toxicity
Based on the results from our experiments with altered Rad23 levels, we hypothesized
that reducing binding of UbS2 to Rad23 would lower Ataxin-3(SCA3) protein levels and
subsequently alleviate its toxicity. We generated additional transgenic flies that express
Ataxin-3(SCA3) with a mutation in UbS2 that was previously shown by us and others to impair
Rad23 binding (Blount et al., 2014; Nicastro et al., 2009; Nicastro et al., 2010), in this case by
approximately 50 percent (Blount et al., 2014). This mutation (referred to as UbS2*Mild) replaces
a critical tryptophan residue on UbS2 with an alanine. It does not alter ataxin-3’s cellular
distribution, or the overall structure of the isolated catalytic domain; it does not negate the ability
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Figure 3.2. Mutating UbS2 does not cause toxicity in wild type ataxin-3, impair binding of ataxin-3 to VCP/p97, or alter the
aggregation propensity of ataxin-3 (Supplemental to Figure 3.3) (A) Adult fly longevity from Drosophilae ubiquitously expressing
Ataxin-3(WT)-UbS2*Mild compared to the same population of control flies that was depicted in Figure 3.1D. Ataxin-3(WT)-UbS2*Mild and
control flies were aged independently. Ubiquitous expression of constructs was driven by the sqh-Gal4 driver. (B) Co-IP from HeLa cells
expressing FLAG-tagged pathogenic ataxin-3 with UbS2 intact or mutated. (C) Western blot of soluble and insoluble fractions from whole,
one-day-old adult flies expressing pathogenic ataxin-3 without or with a mild UbS2 mutation. Transgenes were pan-neuronally expressed
under the control of the elav-Gal4 driver. Both the ataxin-3 band and smear were included in the quantification. (D) Western blot of soluble
and insoluble fractions from whole cell lysates expressing pathogenic ataxin-3 without or with a mild UbS2 mutation. HeLa cells were
transfected with the indicated constructs and harvested 48 hours later. Transfection was conducted such that protein levels of Ataxin-3(SCA3)Intact and UbS2*Mild were comparable among the two groups.

of the full-length protein to become ubiquitinated and catalytically activated; it does not abrogate
the catalytic activity of full-length ataxin-3 ((Blount et al., 2014; Nicastro et al., 2010; Todi et al.,
2010) and data not shown); and, in the context of ataxin-3 with a normal polyQ repeat, this
mutation does not impact fly longevity (Figure 3.2A). This mutation also does not perturb the
ability of ataxin-3 to bind another of its partners, VCP/p97 (Figure 3.2B). Together, these
findings led us to conclude that the conformation of the overall catalytic domain of ataxin-3 is
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not detrimentally impacted by the UbS2*Mild mutation.
Surprisingly, we found that expression of UbS2*Mild throughout the fly causes lethality at
early pupal stages (Figure 3.3A). Western blots from larval lysates demonstrated that mutating
UbS2 reduces Ataxin-3(SCA3) protein levels (Figure 3.3B), confirming our earlier data that
UbS2 is critical for ataxin-3 protein levels. Nevertheless, the lethality phenotype is markedly
worse than what we observe in the flies expressing Ataxin-3(SCA3) with UbS2 intact, which
reach pharate adult and adult stages (Figure 3.3A).
Since these results failed to support our above hypothesis, we pan-neuronally expressed
the Ataxin-3(SCA3) constructs to more thoroughly characterize the phenotype. Western blotting
revealed that mutating UbS2 leads to lower Ataxin-3(SCA3) protein levels (Figure 3.3D),
similar to what was observed with ubiquitous expression in larvae (Figure 3.3B). qRT-PCR
indicates that this is not due to differences at the mRNA level (Figure 3.3C). To examine if
mutating UbS2 alters the aggregation propensity of Ataxin- 3(SCA3) before the onset of
pathology, we performed differential centrifugation of one-day-old flies pan-neuronally
expressing Ataxin-3(SCA3)-Intact or UbS2*Mild. We did not observe a noticeable difference in
soluble/insoluble fractions of Ataxin-3(SCA3)-Intact or UbS2*Mild in flies (Figure 3.2C), or in
mammalian cell culture (Figure 3.2D). When Ataxin-3(SCA3)-Intact is expressed panneuronally, flies exhibit reduced longevity and motility (Figure 3.3E and F). However,
expression of UbS2*Mild triggers greater impairment in longevity and motility than
Ataxin-3(SCA3)-Intact, supporting our results from ubiquitous expression of these two proteins
(Figure 3.3A).
Drosophila eyes are a popular tool for investigating neurodegenerative diseases, as
degeneration can be reliably visualized at the external level or internally through histological
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Figure 3.3. Mutating UbS2 of pathogenic ataxin-3 increases its toxicity. (A) Lethality observed when pathogenic ataxin-3 with or without a
mild UbS2 mutation is ubiquitously expressed. (B) Western blots from larvae ubiquitously expressing pathogenic ataxin-3 with or without a
UbS2 mutation. Expression of constructs in (A) and (B) was driven by the sqh-Gal4 driver. Means ± SD. Asterisks: P < 0.05 from Student’s ttests compared to line 1. Lines 1, 2, and A, B are from different founders, which had similar phenotypic outcomes and were combined in later
studies. (C) qRT-PCR data from one-day-old flies pan-neuronally expressing pathogenic ataxin-3 with or with- out a mild UbS2 mutation.
Endogenous control: rp49. Means ± SD. N.S: non-statistically significant. (D) Western blots from adult flies pan-neuronally expressing pathogenic ataxin-3 with or without a UbS2 mutation. Means ± SD. Asterisks: P < 0.05 from Student’s t-tests compared to line 1. Lines 1, 2, and A,
B are from different founders, which had similar phenotypic outcomes and were combined in later studies. (E) Longevity of flies panneuronally expressing pathogenic ataxin-3 with or without a mild UbS2 mutation. (F) Results from negative geotaxis motility assays, which
were repeated at least three times, totaling at least 100 flies per genotype. Means ± SD. Asterisks: P < 0.05 from Student’s t-tests compared to
Ctrl (black) or Intact (red) for each time point. Ctrl: empty vector inserted into site attP2. Expression of constructs in (C)–(F) was driven by
the elav-Gal4 driver.
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Figure 3.4. Mutating UbS2 increases pathogenicity of ataxin-3 in fly eyes. (A) Western blots from fly heads expressing pathogenic ataxin-3
without or with a UbS2 mutation. Means ± SD. Asterisks: P < 0.05 from Student’s t-tests compared to line 1. Lines 1, 2, and A, B are from
different founders, which had similar phenotypic outcomes and were combined in studies in the other panels of this figure. (B) External photos
and (C) histological sections of fly eyes expressing pathogenic ataxin-3 without or with a mild UbS2 mutation. Ctrl: empty vector inserted into
attP2. White circle in (B): example of the pseudo-pupil. Red boxes in (C): examples of densely-staining aggregates. The precise subcellular
localization of the aggregates is not clear from this assay. Red bracketed lines in (C): examples of disruption of the ommatidial boundaries.
Expression of constructs was driven by the GMR-Gal4 driver.

sectioning. Using the GMR-Gal4 driver, we drove the expression of pathogenic ataxin-3
transgenes in Drosophila eyes to characterize the subsequent degeneration. Once again, we
witnessed a significant reduction in ataxin-3 protein in dissected fly heads expressing UbS2*Mild,
as compared to ones expressing the intact variant (Figure 3.4A). Expressing Ataxin-3(SCA3)Intact in fly eyes leads to a slight depigmentation of the retina, which is visible by day 14 and
increases with age (Figure 3.4B). On day 14, the dark, central pseudo-pupil is also lost,
signifying a compromise of the underlying photoreceptor cells. In the fly eyes expressing
UbS2*Mild, depigmentation and loss of the pseudo-pupil is observed as early as day 7 and
progresses more markedly than with Ataxin-3(SCA3)-Intact (Figure 3.4B).
Next, we performed histology to obtain a more detailed look at the structure of the
internal eye. A healthy Drosophila eye is characterized by an organized ommatidial array with
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distinct boundaries between the ommatidia, the functional unit of the eye. With Ataxin-3(SCA3)Intact, a slight disruption of the ommatidial array is visible at day 7 (Figure 3.4C). By day 14,
darkly staining structures, which were shown previously to contain the pathogenic ataxin-3
protein (Warrick et al., 2005), are visible. At 28 days, the ommatidial array is significantly
degenerated. Compared to the effect of Ataxin-3(SCA3)-Intact, UbS2*Mild causes markedly
increased disorganization of the ommatidial array and the presence of densely-staining structures
as early as day 7. By day 28, the ommatidial boundaries are no longer distinguishable. The data
from Figures 3.3 and 3.4 demonstrate that pathogenic ataxin-3 with mutated UbS2 causes
significantly more degeneration than intact Ataxin-3(SCA3) in various fly tissues.
Our working model predicted that reducing Rad23 binding to Ataxin-3(SCA3) by
mutating UbS2 would decrease Ataxin-3(SCA3) protein levels and lower its toxicity.
Characterization of flies expressing Ataxin-3(SCA3)-Intact or Ataxin-3(SCA3)-UbS2*Mild under
the control of different drivers revealed that mutating UbS2 reduces Ataxin-3(SCA3) protein
levels, but greatly enhances the toxic phenotype. In the fly eyes, this toxicity is concomitant with
the presence of densely-staining aggregates on an earlier time scale with UbS2*Mild than with
Ataxin-3(SCA3)-Intact. The exact type of aggregated species formed by pathogenic ataxin-3 in
vivo is likely to be dependent on cellular context and type of tissue. These results led us to next
probe how disrupting the interaction between Ataxin-3(SCA3) and Rad23 increases the
pathogenicity of the Ataxin-3(SCA3) protein.
3.2.3 Mutating UbS2 increases ataxin-3 toxicity by compromising its autoprotective function
Wild-type ataxin-3 is protective in Drosophila models of polyQ diseases (Burr et al.,
2014; Tsou et al., 2013; Tsou et al., 2015b; Warrick et al., 2005). These findings were supported
by studies in mammalian cell culture where ataxin-3 also protects against various stressors
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(Chatterjee et al., 2015; Reina et al., 2012; Reina et al., 2010; Zhou et al., 2013a). Work
published by the Bonini lab (Warrick et al., 2005) and ours (Tsou et al., 2015b) reported that
wild-type ataxin-3 requires both its catalytic activity and its binding to Rad23 to protect against
polyQ-dependent toxicity in Drosophila. Collectively, these earlier results from flies presented
the possibility that pathogenic ataxin-3 retains the protective function against itself (Figure 3.5A
summarizes the model). We posited that when we mutate UbS2 to reduce Rad23 binding, we
also compromise ataxin-3’s autoprotective function. Without its autoprotection, the UbS2*Mild
protein is more toxic than Ataxin-3(SCA3)-Intact, even though there is less protein present
(Figure 3.5A; also see Figure 3.8A).
To first test whether mutating UbS2 impairs the protective function of Ataxin-3(SCA3),
we co-expressed a polyQ peptide with 78 glutamine repeats (polyQ78) alongside full-length,
pathogenic ataxin-3 transgenes in Drosophila eyes. PolyQ78 is the isolated C terminus of the
ataxin-3 protein without UIMs or the N terminus (Warrick et al., 1998). Fly eyes expressing two
copies of polyQ78 exhibit severe depigmentation of the retina (Figure 3.5B). Indentations are also
visible on the external eye, indicative of the collapse of internal structures. Flies heterozygous for
polyQ78 and the empty host vector for Ataxin-3(SCA3) transgenes display milder, but clearly
visible external depigmentation. Expression of wild-type ataxin-3 ameliorates this phenotype, as
also shown previously (Burr et al., 2014; Tsou et al., 2013; Tsou et al., 2015b; Warrick et al.,
2005). When Ataxin-3(SCA3)-Intact is co-expressed with polyQ78, the level of degeneration is
significantly less than what is observed in flies expressing two polyQ78 alleles. However,
UbS2*Mild is unable to suppress polyQ78 toxicity, supporting the notion that Ataxin-3(SCA3)
retains some protective function, and that mutating UbS2 results in at least some loss of this role.
To further examine the importance of an intact UbS2 on the pathogenicity of the SCA3
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Figure 3.5. Mutating UbS2 of catalytically inactive, pathogenic ataxin-3 reduces its protein levels and toxicity. (A) Table summarizing
the working model for the role of ataxin-3’s UbS2 in toxicity. (B) Photos of external eyes expressing a truncated polyQ fragment of ataxin-3
with 78 repeats and co-expressing the indicated lines. Flies were heterozygous for all transgenes, except for flies homozygous for polyQ78 (far
left). Constructs were expressed using the GMR-Gal4 driver. White arrows: examples of indentation. (C) Western blots from adult flies panneuronally expressing pathogenic ataxin-3 that is catalytically active or inactive. Means ± SD. Black asterisks: P < 0.05 from Student’s t-tests
compared to catalytically active ataxin-3 line 1. Red asterisks: P < 0.05 from Student’s t-tests compared to catalytically inactive ataxin- 3 line
1. Lines 1, 2, and A, B are from different founders, which had similar phenotypic outcomes and were combined in later studies in this figure.
(D) qRT-PCR data from one-day-old flies expressing pathogenic, catalytically inactive ataxin-3 with or without a mild UbS2 mutation.
Endogenous control: rp49. Means ± SD. N.S: non-statistically significant. (E) Longevity data from flies expressing pathogenic, catalytically
inactive ataxin-3 without or with a mild UbS2 mutation. (F) Motility of flies expressing pathogenic, catalytically inactive ataxin-3 without or
with a mild UbS2 mutation. Flies were 7 days old. N = 10, totaling at least 100 flies per genotype. Asterisk: P < 0.05 from Student’s t-tests
compared to C14A-Intact.

protein, we generated additional transgenic fly lines that express catalytically inactive, pathogenic ataxin-3 either with all of its domains intact (Ataxin- 3(SCA3)*C14A -Intact) or with UbS2
mutated

(Ataxin-3(SCA3)*C14A-UbS2*Mild)

(Figure

3.1B).

To

render Ataxin-3(SCA3)
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catalytically inactive, we mutated the critical cysteine in its protease domain to an alanine, which
compromises the protein’s ability to protect against polyQ toxicity (Todi et al., 2007; Todi et al.,
2010; Tsou et al., 2013; Winborn et al., 2008). These transgenic lines would help us to determine
if mutating UbS2 mitigates ataxin-3-dependent toxicity when its autoprotective role is no longer
a factor.
When these catalytically inactive transgenes are pan-neuronally expressed in Drosophila,
the C14A-UbS2*Mild mutation reduces ataxin-3 protein levels, independently of transcriptional
levels (Figure 3.5C and D). The protein levels of catalytically inactive Ataxin-3(SCA3) are also
significantly lower than catalytically active Ataxin-3(SCA3), indicating that ataxin-3’s catalytic
activity regulates its steady state levels in vivo. Importantly, flies expressing C14A-UbS2*Mild
exhibit improved adult longevity compared to the flies with C14A-Intact (Figure 3.5E). Motility
is also significantly improved in C14A-UbS2*Mild flies on day 7 (Figure 3.5F).
Overall, these results indicate that reducing ataxin-3 protein levels can indeed decrease
the toxicity of pathogenic ataxin-3, as long as its protective function is not a factor. We conclude
that UbS2*Mild increased the toxicity of Ataxin-3(SCA3) in our earlier experiments because the
mutation impaired its autoprotective function.
3.2.4 Strong disruption of pathogenic ataxin-3’s UbS2 is less toxic than mild disruption
Mild disruption of Rad23 binding to UbS2, which decreases binding of ataxin-3 to Rad23
in vitro by about 50% (Blount et al., 2014), yielded a more toxic protein. We next reasoned that a
stronger disruption of Rad23 binding to UbS2 might reduce the protein’s toxicity by nearly
eliminating the ataxin-3 protein. To test this possibility, we mutated three amino acid residues of
UbS2 to glutamic acid (Ataxin-3(SCA3)-UbS2*Strong; Figure 3.1B). In vitro binding assays
indicate that UbS2*Strong greatly reduces binding to Rad23 (Figure 3.6A). When we express
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Figure 3.6. A stronger mutation of UbS2 reduces pathogenic ataxin-3 protein levels and toxicity compared to UbS2*Mild. (A) Western
blot from in vitro binding assays of Ataxin-3(WT) and full-length, GST-tagged Rad23A. GST or GST-Rad23 were pulled down on glutathione
agarose beads, washed thrice with NETN and incubated with Ataxin-3(WT)-Intact or Ataxin-3(WT)-UbS2*Strong for 1h on ice. Colored arrows
denote the different amounts of ataxin-3. Percentages compare UbS2-mutated ataxin-3 pulled down by GST-Rad23A to its non-mutated
counterpart of the same amount. (B) Western blots from whole cell lysates. HeLa cells were transfected with the indicated constructs and
harvested 24h later. Means ± SD. Asterisks: P < 0.05 from Student’s t-tests when compared to Intact (black) or UbS2*Mild (purple). (C)
Western blots from HeLa cells transfected with the indicated constructs and treated 24h later with cycloheximide (CHX) for the indicated
amounts of time. Transfection and loading were done such that the protein level of the two different versions of ataxin-3 were comparable at
0h. Example shown is from experiment repeated independently at least 4 times with similar results. (D) Lethality observed when ubiquitously
expressing pathogenic ataxin-3 without or with a UbS2 mutation. (E) Western blots from larvae ubiquitously expressing pathogenic ataxin-3
without or with a strong UbS2 mutation. Means ± SD. Asterisks: P < 0.05 from Student’s t-test compared to Intact. Lines 1 and 2 are from
different founders, which had similar phenotypic outcomes and were combined in phenotypic studies. (F) qRT-PCR data from larvae
ubiquitously expressing pathogenic ataxin-3 without or with a strong UbS2 mutation. Endogenous control: rp49. N.S: non-statistically
significant. (G) Longevity of flies pan-neuronally expressing pathogenic ataxin-3 without or with a UbS2 mutation. (H) Results from motility
assays of flies expressing pathogenic ataxin-3 without or with a UbS2 mutation. Means ± SD. Asterisks: P < 0.05 from Student’s t-tests
compared to Intact (red) or UbS2*Mild (purple). N=10, totaling at least 100 flies per genotype.

pathogenic ataxin-3 with the UbS2*Strong mutation in HeLa cells, we notice a reduction in
Ataxin-3(SCA3) levels more profound than with UbS2*Mild (Figure 3.6B). The turnover rate of
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UbS2*Strong is also higher than that of UbS2*Mild (Figure 3.6C).
We generated additional fly lines that express pathogenic ataxin-3 with the UbS2*Strong
mutation. Ubiquitous expression of UbS2*Strong elicits developmental lethality primarily in the
mid pupal stage, which represents a slight improvement from what was seen earlier with the
UbS2*Mild flies (Figure 3.6D). Western blotting of larvae expressing UbS2*Strong reveals that
ataxin-3 protein levels are reduced by approximately 90% (Figure 3.6E). qRT-PCR indicates that
the decrease in the UbS2*Strong version is not due to transcriptional changes (Figure 3.6F).
We continued our analyses of the SCA3 phenotype by pan-neuronally expressing
UbS2*Strong. When expressed in neurons, the protein levels of this version of ataxin-3 are also
markedly lower than those of the intact counterpart (data not shown), similar to what was
observed with ubiquitous expression in larval lysates (Figure 3.6E). These adults live longer and
perform better in the motility assay than the flies expressing UbS2*Mild (Figure 3.6G and H).
Still, in general they do not perform as well as flies expressing Ataxin-3(SCA3)-Intact.
Collectively, these data further support the role of UbS2 in the pathogenicity of ataxin-3, and
stress the importance of this site on both the toxicity and protein levels of the SCA3 protein.
3.2.5 DnaJ-1 suppresses toxicity from Ataxin-3(SCA3) with mutated UbS2
Previously, we reported that wild-type ataxin-3 (denoted here as Ataxin-3(WT))
suppresses polyQ toxicity in Drosophila by binding Rad23 and leading to an increase in
endogenous DnaJ-1 at mRNA and protein levels (Tsou et al., 2015b). A version of ataxin-3 with
the UbS2*Mild mutation did not have the same effect on DnaJ-1 (Tsou et al., 2015b). DnaJ-1 is a
member of the J/HSP40 family of co-chaperone proteins that maintain the substrate specificity
and stimulate the ATPase activity of HSP70 chaperones (Kampinga and Craig, 2010; Koutras
and Braun, 2014). Since our data are consistent with the idea that Ataxin-3(SCA3) with mutated
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Figure 3.7. Exogenous DnaJ-1 suppresses toxicity from pathogenic ataxin-3 with mutated UbS2. (A) External eye photos and histological
sections of fly eyes expressing pathogenic ataxin-3 with a mild UbS2 mutation in the absence or presence of exogenous DnaJ-1. Constructs
were expressed using the GMR-Gal4 driver. Vector Ctrl: empty vector inserted into attP2. Red boxes: examples of densely-staining structures.
Red bracketed line: an example of disruption of the ommatidial boundaries. (B) Motility of flies expressing pathogenic ataxin-3 with a mild
UbS2 mutation in the presence or absence of exogenous DnaJ-1. Here, elav-Gal4 was on the third chromosome, expressing at lower levels
than in previous figures, where elav-Gal4 was on the X chromosome. Means ± SD. Asterisks: P < 0.05 from Student’s t-test, compared to
UbS2*Mild without exogenous DnaJ-1. N=10, totaling at least 100 flies per genotype. (C) Longevity of flies expressing pathogenic ataxin-3
with a mild UbS2 mutation in the presence or absence of exogenous DnaJ-1. (D) Lethality observed when ubiquitously expressing pathogenic
ataxin-3 with a mild UbS2 mutation in the presence or absence of exogenous DnaJ-1, or wild type ataxin-3, or knockdown of DnaJ-1 through
UAS-RNAi.

UbS2 is more pathogenic due to impaired autoprotection, we tested whether DnaJ-1 can suppress
this toxicity.
When we co-express DnaJ-1 with UbS2*Mild in fly eyes, we observe great improvement in
the internal retinal structure: the boundaries and the organization of the ommatidia are restored
(Figure 3.7A). External photos of DnaJ-1 eyes display the reappearance of the pseudo-pupil,
consistent with a healthy underlying structure (Figure 3.7A). Pan-neuronal expression of DnaJ-1
alongside UbS2*Mild also improves adult longevity and motility (Figure 3.7B and C). Moreover,
exogenous DnaJ-1 reduces the rate of developmental lethality in UbS2*Mild flies when the toxic
protein is expressed everywhere (Figure 3.7D). Instead of dying in the early pupal stage, these
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flies exhibit late pupal and pharate adult lethality. A small number of adults even successfully
eclose and survive for two or three days. Importantly, RNAi-dependent knockdown of DnaJ-1
causes the UbS2*Mild flies to die much earlier (Figure 3.7D).
Lastly, we examined the protective role of Ataxin-3(WT) against its pathogenic variant
with UbS2 mutated. As summarized in Figure 3.7D, expression of non-pathogenic ataxin-3 has a
suppressive effect towards UbS2*Mild that closely mirrors the protective effect of exogenous
DnaJ-1. Ataxin-3(WT) delays lethality from pathogenic ataxin-3 with a mutated Rad23-binding
site from early pupal to late pupal and pharate adult stages. A handful of adults eclose and
survive for a few days. Altogether, the results in Figure 3.7 lend additional support to the
hypothesis that pathogenic ataxin-3 with mutated UbS2 is more toxic due to a perturbation of its
autoprotective role.
Wild-type ataxin-3 has a protective effect against various polyQ proteins in Drosophila
(Burr et al., 2014; Tsou et al., 2013; Tsou et al., 2015b; Warrick et al., 2005). This role of
ataxin-3 in the fly depends on its catalytic activity, on an intact UbS2, and on the presence of
Rad23 (Tsou et al., 2015b; Warrick et al., 2005). According to those findings, ataxin-3, in a
manner dependent on Rad23, leads to an increase in the transcription of DnaJ-1 and a subsequent
rise in its protein levels. This co-chaperone then functions with inducible heat shock proteins to
reduce the aggregation and toxicity of polyQ species in flies. The data in Figure 3.7, together
with the results from prior figures where we perturbed Rad23 levels, mutated UbS2 of ataxin-3,
and incapacitated the DUB activity of pathogenic ataxin-3, collectively indicate a similar
mechanism at work on autoprotection from pathogenic ataxin-3.
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Figure 3.8. Model of Rad23 and UbS2 regulating ataxin-3’s levels and toxicity. (A) Knocking down Rad23 reduces its availability to bind
ataxin-3 at UbS2, increasing ataxin-3’s degradation. This reduces ataxin-3 protein levels while leaving its autoprotection intact, resulting in
lowered ataxin-3 toxicity. (B) Ataxin-3 with intact UbS2 is present at baseline levels; its pathogenicity is regulated by its autoprotection, which
requires Rad23 binding to UbS2. (C) Exogenous Rad23 increases its availability to bind ataxin-3, inhibiting ataxin-3’s proteasomal
degradation and increasing its toxicity. (D) Mutating UbS2 reduces Rad23 binding, resulting in lower ataxin-3 levels. However, mutating this
site compromises ataxin-3’s protection against itself, thus increasing its toxicity.

3.3 Discussion
Our prior work showed a critical role for the SCA3 protein interaction with the
proteasome-associated protein, Rad23 in the proteasomal turnover of ataxin-3 (Blount et al.,
2014). Whether the site of this interaction was directly important for the toxicity of the SCA3
protein, or if targeting this interaction could be beneficial against SCA3, was unclear. We found
that mutating UbS2 on ataxin-3 to disrupt this interaction substantially reduces steady state levels
of the SCA3 protein in vivo, but greatly enhances its toxicity. According to our work, ataxin-3’s
binding to Rad23 regulates this polyQ protein’s levels, autoprotective function, and,
consequently, its pathogenicity. The data presented here showcase a previously unreported role

44
for the interaction between the SCA3 protein and Rad23 as a regulator of ataxin-3’s own
pathogenicity in an intact, model organism (Figure 3.8). Our results bring together a new
understanding of the role of ataxin- 3’s domains and its interactions with partners in its toxicity.
They also highlight the importance of protein context in the biology of this polyQ disease, and
the need to carefully consider it when devising strategies for suppressive avenues.
Ataxin-3 can also bind ubiquitin through UbS2 (Nicastro et al., 2009; Nicastro et al.,
2010). One might surmise that binding of ubiquitin, or other similar proteins, could potentially
impact ataxin-3 levels and toxicity through their interaction with UbS2. In earlier work, we
found that knockdown of ubiquitin-like proteins did not impact ataxin-3 levels in Drosophila
(Blount et al., 2014). Our genetic manipulations of Rad23 levels in this study and in other,
previously published work (Blount et al., 2014) make a strong case for a specific and significant
role from the binding of ataxin-3 to Rad23 in the toxicity and levels of the SCA3 protein.
Ataxin-3’s interaction with Rad23 might have a cellular role by assisting with the
degradation of select poly-ubiquitinated substrates destined for the proteasome ((Buchberger et
al., 2010; Dantuma et al., 2009). Binding of ataxin-3 to Rad23 hinders the degradation of the
SCA3 protein (Blount et al., 2014). This interaction between Rad23 and ataxin-3, however, need
not impact the ability of these two ubiquitin-binding proteins to deliver cargo to the degradative
machinery, which depends on the transfer of poly-ubiquitinated substrates from shuttles to the
19S component of the proteasome (Ristic et al., 2014).
Our findings raise the question why we observe decreased ataxin-3-dependent toxicity
when we reduce Rad23 levels through RNAi, but not when we mutate UbS2 to reduce Rad23
binding to ataxin-3. Rad23 knockdown reduces its levels and thus ataxin-3 protein levels as a
result of its increased degradation (Figure 3.1A; (Blount et al., 2014)), but the remaining Rad23
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and ataxin-3 proteins can still interact since UbS2 is intact. In this scenario, ataxin-3 is likely less
toxic because some of the pathogenic protein is eliminated, but the remaining SCA3 protein can
still bind Rad23 and exert its unperturbed autoprotective role. When we mutate UbS2, we reduce
the protective ability of all of the ataxin-3 protein present as a result of compromised binding to
Rad23 (Figure 3.8). Ataxin-3 with mutated UbS2 is unable to elevate expression of the cochaperone DnaJ-1 (Tsou et al., 2015b). Thus, it is not surprising that when we increase the levels
of DnaJ-1, we observe a reduction in the pathogenicity of ataxin-3 with mutated UbS2.
Various studies have reported that reducing levels of disease proteins improves the
pathology in SCA3 and other polyQ disorders (Alves et al., 2010; Harper et al., 2005; Pedersen
and Heegaard, 2013; Tsou et al., 2011; Williams et al., 2009; Williams and Paulson, 2008; Xia et
al., 2004). Our work demonstrates that the means by which pathogenic protein levels are reduced
can influence its toxicity. Since UbS2 is important for both ataxin-3’s protein levels and
autoprotective function, genetically mutating this site to prevent Rad23 binding proved
inadequate for simultaneously reducing ataxin-3 levels and its toxicity. Thus, pathogenic protein
levels cannot be reduced indiscriminately; the functionality of the protein binding domains and
its interactions must be considered before targeting it therapeutically.
Our results show that mutating UbS2 exacerbates, rather than alleviates, ataxin-3dependent toxicity in Drosophila. The question remains whether UbS2 could be a potential
therapeutic target for SCA3 in mammalian systems. The toxicity from mutating UbS2 in flies
results from disruption of ataxin-3’s protective role. While a protective role for ataxin-3 in flies
and mammalian cells is clear (Burr et al., 2014; Chatterjee et al., 2015; Reina et al., 2012; Reina
et al., 2010; Tsou et al., 2013; Tsou et al., 2015b; Warrick et al., 2005; Zhou et al., 2013a), there
is conflicting evidence for a similar role for ataxin-3 in mice. In one study, SCA3 transgenic mice
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that were heterozygous for pathogenic ataxin-3 and possessed one copy of wild-type ataxin-3
exhibited a milder phenotype than mice expressing pathogenic ataxin-3 alone (Cemal et al.,
2002) Alternatively, co-expression of wild-type ataxin-3 in a different SCA3 mouse model did
not ameliorate the phenotype (Hubener and Riess, 2010). Yet another study reported that
complete loss of endogenous, wild-type ataxin-3 in a mouse model of Huntington’s disease
exacerbated a motor phenotype, but it did not affect other aspects of the pathology (Zeng et al.,
2013). If ataxin-3 does not play a significant protective role in intact mammals, mutating UbS2
in situ could be a potential therapeutic approach for SCA3, as this should reduce ataxin-3 protein
levels without causing much additional toxicity. Since ataxin-3’s neuroprotective role in
mammals remains to be fully clarified, our work suggests that the ideal approach for SCA3
therapy should aim to reduce ataxin-3 levels while leaving its autoprotection intact.
In conclusion, the interaction of ataxin-3 with Rad23 through the UbS2 domain appears
to serve dual roles on the SCA3 protein by regulating its levels and inherent toxicity. Our
findings provide novel clues towards the understanding of the biology of disease in SCA3, and
caution against arbitrarily reducing the levels of a toxic protein for the purposes of therapy. The
next chapter will investigate the interaction of ataxin-3 with another one of its binding partners,
VCP.
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CHAPTER 4: Toxicity and aggregation of the polyglutamine disease protein, ataxin-3, is
regulated by its binding to VCP/p97 in Drosophila melanogaster
Under review: Ristic G*, Sutton JR*, Libohova K, Todi SV (2018). Toxicity and aggregation of
the polyglutamine disease protein, ataxin-3 is regulated by its binding to VCP/p97 in Drosophila
melanogaster. Neurobiology of Disease. *- these authors contributed equally to this manuscript.
4.1 Introduction
The previous chapter explored ataxin-3's interaction with Rad23, an interaction partner
that is linked to ataxin-3’s neuroprotective function. Another protein quality control partner of
ataxin-3 is Valosin-Containing Protein (VCP, also known as p97), a member of the AAA
(ATPases Associated with diverse cellular Activities) family of proteins (Figure 4.1A-B) (Meyer
et al., 2012). VCP functions as a homo-hexamer, converting chemical energy harvested from ATP
hydrolysis to mechanical energy to exert force on its substrates. It is an essential, ubiquitously
expressed protein involved in numerous cellular processes, including protein degradation (Xia et
al., 2016).
Ataxin-3 binds VCP directly (Doss-Pepe et al., 2003; Hirabayashi et al., 2001; Wang et
al., 2006) through a region on its C-terminal half (Figure 4.1A) (Boeddrich et al., 2006).
According to biochemical and cell-based experiments from an elegant study by the Wanker and
Bonini labs, ataxin-3 binds to the N-terminal portion of VCP through an arginine-rich area
(amino acid sequence RKRR) (Boeddrich et al., 2006) (Figure 4.1A). Mutating the VCP-binding
site on ataxin-3 disrupts the interaction between these two proteins (Boeddrich et al., 2006). The
same study also reported that VCP stimulates fibrillogenesis/aggregation of pathogenic ataxin-3
in a dose-dependent manner in in vitro, reconstituted systems. These results suggested a seeding
role for VCP: the hexamer binds multiple ataxin-3 proteins, increasing their chances of
interacting together and enhancing their initial aggregation (Boeddrich et al., 2006). Exogenous
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VCP mitigated, to some extent, degeneration caused by full-length, pathogenic ataxin-3 in one
tissue tested: the eyes of fruit flies (Boeddrich et al., 2006). These compelling data highlight the
need for additional examinations to understand the interaction between ataxin-3 and VCP in vivo.
Direct comparison between pathogenic ataxin-3 that can bind VCP and a version that has the
VCP-binding site mutated—expressed similarly in various tissues— is necessary to appreciate
the interplay between these proteins in SCA3. It would also help overall understanding of SCA3
biology to examine if VCP regulates the aggregative propensity of pathogenic ataxin-3 in an
intact animal, beyond in vitro settings. Lastly, examining the relationship of the VCP-ataxin-3
interaction to the temporal aggregation and pathogenicity of the SCA3 protein in an intact animal
would be helpful both to further our knowledge of SCA3 disease mechanisms and to examine if
this interaction could be of therapeutic benefit. These were the various aspects that we set out to
tackle in this work, by using Drosophila as a model organism.
To accomplish this, we generated isogenic lines of Drosophila melanogaster that express,
in a Gal4-UAS-dependent manner (Brand et al., 1994; Brand and Perrimon, 1993), full-length,
human, pathogenic ataxin-3 with a normal or mutated VCP-binding site. We found that
pathogenic ataxin-3 with a mutated VCP-binding site is markedly less toxic in flies, even though
the protein is present at levels similar to its VCP-binding counterpart. Initially, flies that express
the SCA3 protein with impaired VCP-binding are indistinguishable from controls that do not
express any pathogenic ataxin-3. This coincides with markedly lower levels of aggregated
ataxin-3 species. Altering the levels of endogenous VCP protein modulates the toxicity of the
SCA3 protein in a manner that supports the idea of a nucleation role for the aggregation of
ataxin-3 by this AAA ATPase. Our data highlight an important physiological role for VCP on
ataxin-3-dependent degeneration and underscore the importance of non-polyQ regions of this
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DUB to the toxicity of its expanded repeat.
4.2 Results
4.2.1 Mutating the VCP-binding site of ataxin-3 disrupts its interaction with VCP in flies
We began our journey into the role of the VCP-ataxin-3 interaction in SCA3-like degeneration in Drosophila by confirming that the VCP-binding site mutation, “RKRR” to “HNHH",
disrupts the DUB’s interaction with fly VCP. This mutation was shown before to disrupt binding
of recombinant ataxin-3 to mammalian VCP (Boeddrich et al., 2006). We generated recombinant,
pathogenic ataxin-3 with 80 polyQ in bacterial cells. This repeat is within patient range. We
produced two versions of the DUB: one that has the intact VCP-binding site and one whose site
is mutated from “RKRR” to "HNHH". We then incubated bead-bound, GST-tagged, recombinant
ataxin-3 with whole fly lysates and probed for the ability of human ataxin-3 to interact with fly
VCP. As shown in Figure 4.1C, the pathogenic version of ataxin-3 co-precipitates fly VCP,
whereas the version with impaired VCP-binding has a drastically reduced capacity to bind fly
VCP; the western blot signal was barely above non-specific background that was non-specifically
brought down by GST alone (Figure 4.1C). This disruption in interaction between VCP and
ataxin- 3 is similar to what we observe in mammalian cells: pathogenic ataxin-3 with impaired
VCP-binding is unable to co-IP endogenous, human VCP beyond non-specific background,
whereas pathogenic ataxin-3 with intact VCP-binding co-IPs this interactor (Figure 4.1D). In
Figures 4.1C and D, we used mild conditions that brought down some VCP non-specifically,
which helped us to not exclude the possibility of residual VCP interaction with VCP-bindingmutated ataxin-3. We did not observe clear and specific interaction of VCP with pathogenic
ataxin-3 that has its VCP-binding site mutated. Lastly, as shown in Figure 4.1E, mutating the
RKRR region on pathogenic ataxin-3 removes its ability to bind fly VCP in vivo. In this last
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Figure 4.1. Pathogenic ataxin-3 with a mutated VCP-binding site does not bind Drosophila VCP. (A) Diagrammatic representation of
ataxin-3. The catalytic domain of ataxin-3, Josephin Domain, is located at the structured N-terminal half of the protein. The inherently unstructured C-terminal portion contains three Ubiquitin Interacting Motifs (UIMs), the polyQ tract (which is abnormally expanded in SCA3
patients), and the VCP-binding site. Box shows this site was mutated from “RKRR” to “HNHH” to disrupt the interaction with VCP. (B)
Diagrammatic representation of VCP. VCP functions as a homohexamer. Each VCP protein contains an N-terminal domain (through which it
binds to most of its co-factors, including ataxin-3), two tandem ATPase domains, and a short C-terminal tail. (C) Western blot from in vitro
pulldowns with whole fly lysates and immobilized, recombinant GST, GST-Ataxin-3(SCA3)-Intact, or GST-Ataxin-3(SCA3)-HNHH. Both
Ataxin-3(SCA3) constructs contained 80 polyQ repeats. Blots are representative of experiments repeated independently three times with the
same outcomes. (D) Western blot of co-immunoprecipitations from HEK293 cells transiently transfected with the indicated constructs. Blots
are representative of experiments repeated independently three times with the same outcomes. NS=Nonspecific band we often observe with
the polyclonal ataxin-3 antibody. (E) Western blot of co-immunoprecipitations from dissected heads of transgenic flies expressing the
indicated constructs. Transgenes were expressed through the eye-specific GMR-Gal4 driver. Blots are representative of experiment repeated
independently three times with the same outcomes. In this panel and the rest of the figures, flies were heterozygous for all drivers and
transgenes, unless otherwise noted. (F) qRT-PCR results from whole adult flies expressing pathogenic ataxin-3 with an intact or mutated VCPbinding site. Ataxin-3(SCA3)-Intact or Ataxin-3(SCA3)-HNHH was driven by the sqh-Gal4 ubiquitous driver. No significant differences in the
mRNA expression levels were observed when the VCP-binding site is mutated to HNHH. N=4 independent repeats. In this panel and the rest
of the figures, HNHH 1 and 2 are independently derived transgenic lines. Endogenous control: rp49. Means ± SD. P values were calculated by
two-tailed Student’s t-tests, comparing HNHH 1 and HNHH 2 to Intact. (G) Western blot of fly lysates after cytoplasmic/nuclear centrifugal
fractionation. Transgenic adult flies expressed pathogenic ataxin-3 with or without the VCP-binding site mutated from “RKRR” to “HNHH”.
Ataxin-3(SCA3)-Intact or Ataxin-3(SCA3)-HNHH were expressed under the control of the sqh-Gal4 driver. “Intact Control” flies were
Ataxin-3(SCA3)-Intact-encoding flies without a driver. Asterisks: ubiquitinated ataxin-3. NS=Nonspecific band. Blots are representative of
experiments repeated independently three times with the same outcomes.
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setup, we co-expressed HA-tagged, fly VCP alongside ataxin-3 in fly eyes and precipitated VCP.
HA-tagged, Drosophila VCP is able to co-IP pathogenic ataxin-3 with an intact VCP-binding
site, but not the pathogenic version with the “RKRR to HNHH" mutation (Figure 4.1E). We
conclude that this specific mutation on pathogenic ataxin-3 effectively disrupts the interaction of
the SCA3 protein with Drosophila VCP.
4.2.2 Mutating the VCP-binding site of ataxin-3 does not alter its protein or mRNA levels, or
its subcellular localization
At hand, we have flies that express pathogenic ataxin-3 with an intact or mutated VCPbinding site. We generated the full-length, human, pathogenic ataxin-3 for earlier work (Chapter
3). For the present work, we created new transgenic Drosophila lines expressing ataxin-3 with 80
polyQ repeats with the “RKRR” to “HNHH" mutation. The new lines were constructed by
cloning this ataxin-3 transgene into the pWalium10-moe vector, which was used with the phiC31
site-specific integrase system to insert the construct at the attP2 site on the third chromosome of
the fly (Groth et al., 2004; Tsou et al., 2016). These flies are referred to as "HNHH" 1 and 2, as
we utilized two independently-derived lines, which ultimately led to the same results that were
combined in most figures. The “HNHH" lines are isogenic to the “Intact” SCA3 line; the
constructs are each inserted into attP2, in the same orientation and as a single copy (Groth et al.,
2004).
First, we wanted to confirm that any difference in phenotype we might observe among
the different lines is not due to a change in ataxin-3 transgene expression levels. We examined
mRNA expression levels of ataxin-3 by qRT-PCR when the protein was expressed in the whole
fly using the ubiquitous driver sqh-Gal4 (Figure 4.1F). The "HNHH"-1 and -2 lines were
compared to the line expressing pathogenic ataxin-3 with an intact VCP-binding site. There is no
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statistically significant difference in the expression levels of ataxin-3 among the three fly lines.
Our lab also showed previously that ataxin-3 turnover is not affected when the VCP-binding site
was mutated in mammalian cells (Blount et al., 2014) or in Drosophila (Tsou et al., 2015b).
The VCP-binding site on ataxin-3 is an arginine-rich region located at the C-terminus of
ataxin-3. Previously, this domain was thought to encode a nuclear localization signal (Albrecht et
al., 2004). We examined whether mutating the VCP-binding site affects the localization of
pathogenic ataxin-3 in the fly. We used centrifugal fractionation to enrich cytoplasmic and
nuclear proteins from whole fly lysates when pathogenic ataxin-3 expression is driven by the
ubiquitous driver, sqh-Gal4. After analysis by western blotting and probing with ataxin-3
antibody, we observed no difference in protein distribution between the cytoplasm and nucleus
when the VCP-binding site is mutated (Figure 4.1G). We conclude that mutating the VCPbinding site from “RKRR” to "HNHH" does not impact the cellular localization of pathogenic
ataxin-3 in the fly.
4.2.3 Mutating the VCP-binding site of pathogenic ataxin-3 reduces its toxicity in Drosophila
To physiologically assess how mutating the VCP-binding site affects the toxicity of
ataxin-3 in Drosophila, we conducted longevity studies. As we reported previously (Chapter 3),
pathogenic ataxin-3 is highly toxic to the fly when it is expressed ubiquitously. We observe death
during late pharate adult stages, during eclosion from the pupal case, and shortly following
eclosion (Figure 4.2A). Those flies that successfully eclose survive for about 30 days (Figure
4.2B); as a frame of reference, flies not expressing pathogenic ataxin-3 can live up to ~90 days
(Chapter 3). "HNHH" mutant flies all reached adulthood (Figure 4.2A). We did not observe
death during development as we had with flies encoding ataxin-3 with the intact VCP-binding
site. From longevity data (Figure 4.2B), we observed a clear separation in the rates of death
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Figure 4.2. Mutating the VCP-binding site of pathogenic ataxin-3 delays its aggregation and toxicity when expressed in all fly tissues. In
all panels, transgenes were expressed using the ubiquitous sqh-Gal4 driver. (A) Summary of effects on fly development and longevity when
pathogenic ataxin-3 with an intact or mutated VCP-binding site is expressed in all fly tissues. (B) Longevity of adult flies ubiquitously
expressing pathogenic ataxin-3 with or without the VCP-binding site mutated from RKRR to HNHH. Control flies contained the sqh-Gal4 driver
and the empty cloning vector (pWalium10-moe) inserted at the attP2 site, without an ataxin-3 transgene. Control flies lived up to ~90 days. (C,
D) Western blots from one-day-old flies (C) or flies of different ages (D) expressing pathogenic ataxin-3 with or without a mutation in the VCPbinding site. HNHH 1 and 2 are independently derived transgenic lines. Results are representative of experiments repeated independently at least
three times with the same outcomes. In (C-E), and the rest of the figures in this manuscript, dotted lines help to visually categorize ataxin-3
species into SDS-soluble and SDS-resistant. Asterisks: ubiquitinated ataxin-3. (E) Western blot from differential centrifugation of fly lysates into
soluble supernatant and insoluble pellet fractions. Lysates are from 1-, 7-, or 14-day-old flies ubiquitously expressing pathogenic ataxin-3 with
or without a mutated VCP-binding site. Ten μg of supernatant and 7 μl of pellet fractions were electrophoresed on 4-20% gradient gels. Results
are representative of experiments repeated independently at least three times with the same outcomes.

early on: the "HNHH" mutant-expressing flies appear healthier and more flies remain alive in the
earlier days of life than their “Intact” ataxin-3-expressing counterparts (Figure 4.2B). Whereas
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about 25% of flies that express Ataxin-3(SCA3)-Intact are dead before day 5, 25% of flies
expressing the “HNHH" counterparts are dead by day 17. As more flies die, we observe that
about 50% of flies expressing “Intact” pathogenic ataxin-3 are gone by day 13, compared to
"HNHH" mutant-expressing flies which reach 50% death around day 21. When compared with
the control flies that do not express pathogenic ataxin-3, both “Intact” and “HNHH” live a
lifespan that is markedly shorter (Figure 4.2B). Control flies in this experiment contain the
cloning vector (pWalium10-moe; inserted at the attP2 site), without any ataxin-3 transgenes, and
the sqh-Gal4 driver. Still, the “HNHH” mutation has a dramatic, early impact on the longevity of
these flies when the transgene is expressed in all tissues of the fruit fly.
Next, we assessed by western blotting the expression of ataxin-3 protein in one-day-old,
whole-fly lysates where pathogenic ataxin-3 with an intact or mutated VCP-binding site was
expressed using sqh-Gal4. Flies which harbor pathogenic ataxin-3 with intact VCP-binding show
higher-molecular weight species, indicative of ataxin-3 SDS-resistant aggregates as early as one
day after eclosion, whereas flies with a mutated VCP-binding site do not show this high
molecular weight smear (Figure 4.2C).
In Figure 4.2C and throughout the rest of this work, you will observe several ataxin-3positive bands in western blots. The band highlighted as SDS-soluble species contains the
unmodified version of this protein (bottom-most band) and what could be a phosphorylated form
of ataxin-3 (immediately above it in lighter exposures in some instances; this band is not always
visible) (Fei et al., 2007; Kristensen et al., 2017; Matos et al., 2016). The asterisks denote
ubiquitinated species of ataxin-3, based on our earlier studies with this protein in vitro, in
mammalian cells and in Drosophila (Todi et al., 2010; Todi et al., 2009; Tsou et al., 2013). We
have drawn a dotted line to separate what we know are unmodified and ubiquitinated species of
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ataxin-3 from the higher-molecular weight species. The smear above the dotted line is consistent
with SDS-resistant ataxin-3 species, based on our earlier work with this protein (Blount et al.,
2014; Scaglione et al., 2011; Todi et al., 2009; Tsou et al., 2013; Tsou et al., 2015b). In our
extensive work with this protein in vitro, in mammalian cells, in Drosophila and in mouse
models of this disease, we are confident that our delineation by the dotted line is a reasonable
classification of ataxin-3 species that are SDS-soluble vs. not. The SDS- resistant species may
contain higher-order aggregates of the SCA3 protein.
As already noted, SCA3 is an age-related, progressive neurodegenerative disease. While
aging the flies in the longevity experiment, we collected adults for western blot analysis after
eclosion on day 1, 7 and 14 to examine the state of SDS-resistant and SDS-soluble species as
flies age (Figure 4.2D). We observe that on day 1, SDS-resistant species are already clearly
present in flies that express the “Intact” pathogenic protein, whereas, with "HNHH" mutant flies,
we see clear accumulation of SDS-resistant protein species on day 7. On day 1, "HNHH" flies
have noticeably less SDS-resistant species than “Intact” counterparts. Both “Intact” and
"HNHH" flies show SDS-resistant species with age, but this accumulation is delayed in the
“HNHH” flies.
To further examine the accumulation of insoluble aggregates of ataxin-3 with an intact or
mutated VCP-binding site, we utilized differential centrifugation to separate whole fly lysates
into a soluble, supernatant fraction and an insoluble, pellet fraction (Figure 4.2E) (Kim et al.,
2011; O'Rourke et al., 2013; Santarriaga et al., 2015; Yang et al., 2014). We noticed a trend
similar to what we saw with the SDS-resistant species in the previous panel, confirming our
categorization of those species as aggregated ataxin-3. Flies expressing ataxin-3 with intact VCPbinding contain insoluble ataxin-3 aggregates in the pellet fraction as early as day 1, and
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accumulate over time. Flies expressing pathogenic ataxin-3 with impaired VCP-binding do not
exhibit marked insoluble aggregates in the pellet until day 7. Accumulation of these species
occurs with time, but is delayed compared to ataxin-3 with intact VCP-binding, similar to what
we observe with SDS-resistant species in earlier blots.
Altogether, these experiments indicate that when the VCP-binding site of pathogenic
ataxin-3 is mutated, there is a delay in the accumulation of aggregated protein species in flies as
compared to their “Intact", pathogenic ataxin-3-expressing counterparts. Disrupting the
interaction between pathogenic ataxin-3 and VCP leads to markedly lower toxicity from
pathogenic ataxin-3 during development and early on in the life of adult flies. These results
prompted us to next explore the physiological impact of this mutation on the nervous system, the
primary site of pathology in SCA3.
4.2.4 Pathogenic ataxin-3 with mutated VCP-binding is less toxic in fly neurons
Ataxin-3 is expressed in all tissues and cells in the human body. However, the polyQ
disease SCA3 manifests as a neurodegenerative disorder with degeneration specifically in the
brainstem and the cerebellum (Costa Mdo and Paulson, 2012). With fly genetics, we can direct
the expression of ataxin-3 only in the nervous system using a neuronal-specific driver, elav-Gal4,
and examine its effects in the fly.
Western blot analysis from one-day-old whole-fly lysates where pathogenic ataxin-3 with
an intact VCP-binding site is expressed pan-neuronally shows the presence of SDS-resistant
ataxin-3 as early as day one in adults (Figure 4.3A). Comparing the impaired VCP-binding flies
to those expressing the “Intact” protein, the high molecular weight smear is largely absent. The
control flies used in this experiment were ones which contain the “Intact” pathogenic ataxin-3
transgene without the pan-neuronal driver; thus, there was no ataxin-3 expression in these flies.
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Figure 4.3. Mutating the VCP-binding site of pathogenic ataxin-3 delays its aggregation and toxicity when expressed pan-neuronally.
In all panels, transgenes were expressed using the pan-neuronal elav-Gal4 driver. (A, C) Western blots from one-day-old flies (A) or flies of
different ages (C) when pathogenic ataxin-3 with or without a mutation of its VCP-binding site is expressed in the nervous system. Control
flies contained the Ataxin-3(SCA3)-Intact transgene, but without a Gal4 driver. Blots are representative of experiments repeated independently
five times with the same outcomes. NS: nonspecific band we observe sometimes with the monoclonal anti-ataxin-3 antibody when this
transgene is expressed pan-neuronally. (B) Longevity assay from adult Drosophilae pan-neuronally expressing pathogenic ataxin-3 with an
intact or mutated VCP-binding site. Control flies contained the empty pWalium10-moe vector, without a transgene inserted at attP2, in the
presence of the elav-Gal4 driver. Control flies lived up to ~90 days.

Next, we aged adults to investigate how ataxin-3 expression in the nervous system affects
their lifespan. Similarly to results we obtained when ataxin-3 forms are expressed in all tissues
(Figure 4.2B), pan-neuronal expression of the VCP-binding site mutant delays lethality in adults
compared to the “Intact” form (Figure 4.3B). A higher percentage of flies remain alive early on;
we observed a 50% loss of flies expressing pathogenic ataxin-3 with intact VCP-binding by day
25 whereas this reduction occurs around day 35 in flies expressing pathogenic ataxin-3 with
impaired VCP-binding. However, even though in earlier time points more mutant “HNHH” flies
remain alive, both fly lines have an average life span of 45 to 50 days (Figure 4.3B). Flies pan-
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neuronally expressing either variant of pathogenic ataxin-3
live longer than those expressing the same constructs
ubiquitously with the sqh-Gal4 driver. The difference in
toxicity observed in this case is likely due to expression
in all tissues of the fly as compared to only in the nervous
system.
We examined by western blotting whole fly lysates
at three points: day 1, day 7, and day 14 (Figure 4.3C).
Similar to the results with ubiquitous expression of
ataxin-3,

(Figure

4.2D),

SDS-resistant

pathogenic

ataxin-3 species are evident at day one in flies expressing
the protein with intact VCP-binding (Figure 4.3C).
Conversely, in those flies expressing pathogenic ataxin-3
with impaired VCP-binding, high molecular weight
species are not prominent until day 7 (Figure 4.3C).
SCA3 is a movement disorder, marked by
progressive ataxia followed by death (Costa Mdo and
Paulson, 2012). We tested neuronal function of flies when
the

pathogenic

ataxin-3

proteins

were

expressed

Figure 4.4. Flies that express pathogenic ataxin-3 with a mutated VCP-binding site are indistinguishable from non-ataxin-3 flies early
on in motility assays. Results from a negative geotaxis assay used to assess the motility of flies expressing pathogenic ataxin-3 with or
without the VCP-binding site mutation from “RKRR” to "HNHH". Ataxin-3 transgenes were expressed using the pan-neuronal elav-Gal4
driver. Histograms show the mean ± SD, expressed as a percentage, of flies able to reach the top of the vial at the indicated time points.
Asterisks: P<0.05, compared to “No Ataxin-3” control flies. P values are from two-tailed Student’s t-tests, comparing “Intact” and “HNHH” to
“No Ataxin-3”. “No Ataxin-3” flies contained the elav-Gal4 driver and the empty pWalium10-moe vector inserted into the attP2 site. N=5
independent repeats, totaling at least 50 flies per genotype.
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specifically in the nervous system by examining their motility against the gravitational index. We
assessed how many flies reach the top of the vial within 5, 15 and 30 seconds. Adult flies were
maintained over a period of four weeks and motility was assessed weekly (Figure 4.4). As early
as day seven, flies expressing the “Intact” pathogenic protein are slower than control flies
containing the empty vector across all three time points. This difference increases markedly with
age, and at four weeks of age the majority of flies do not reach the top of the vial even during the
longest time interval, 30 seconds. Conversely, flies expressing pathogenic ataxin-3 with a
mutated VCP-binding site perform as well as control counterparts for up to three weeks of age
(Figure 4.4). We did not notice statistically significant reduction in the motili- ty of these flies
early on, a testament to the reduced toxicity of this protein in neurons, compared to the “Intact”
counterparts. Finally, at four weeks of age, the “HNHH” flies also show slower motility
compared to non-ataxin-3-expressing controls, but still perform markedly better than flies
expressing pathogenic ataxin-3 with intact VCP-binding (Figure 4.4).
In conclusion, when the VCP-binding site of ataxin-3 is mutated, accumulation of SDSresistant species in neurons is delayed, as also observed with ubiquitous expression of the
respective proteins. Flies pan-neuronally expressing pathogenic ataxin-3 with a mutated VCPbinding site perform significantly better than their “Intact” pathogenic ataxin-3-expressing
counterparts in the negative geotaxis motility assay, comparable to control flies until three weeks
of age. Reduced performance by the flies expressing pathogenic ataxin-3 with a mutated VCPbinding site occurs after noticeable accumulation of SDS-resistant species by western blotting
(Figure 4.3C), indicating a temporal relationship between aggregation and toxicity.
4.2.5 Ataxin-3 with a mutated VCP-binding site is less toxic in Drosophila eyes
Drosophila eyes serve as a widely accepted model to study degeneration in polyQ
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diseases and other proteotoxic disorders (Bonini and Fortini, 2003; Kim et al., 2018).
Histological sections of the fly eye allow visualization of degeneration and accumulation of
proteinaceous aggregates. Using the GMR-Gal4 driver, we expressed the Ataxin-3(SCA3)
transgenes in fly eyes and conducted histological assays at different time points to characterize
the degeneration caused
by

expression

“Intact”

of

pathogenic

ataxin-3 and the effects
of mutating the VCPbinding

site

on

the

phenotype.
The ommatidium is
the functional unit of
the fly eye. Each eye
contains approximately
800

ommatidia

arranged in a structured
array.

The

highly

iterative structure of the
eye makes it a good

Figure 4.5. Disrupting the interaction between ataxin-3 and VCP reduces toxicity in fly eyes. In all panels, transgenes were expressed using
the eye-specific GMR-Gal4 driver. (A, B) Histological sections of fly eyes expressing pathogenic ataxin-3 with or without a mutation in the
VCP-binding site at one week (A) or four weeks (B) of age. Vector Control flies contain the GMR-Gal4 driver, as well as the empty
pWalium10-moe vector inserted at attP2. Red boxes: example of densely-staining structures. (C) Western blots from lysates of fly heads
dissected from one-day-old flies. Fly eyes expressed pathogenic ataxin-3 with an intact or mutated VCP-binding site. Blots are representative
of experiments repeated independently at least 5 times with the same outcomes.
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model to easily and reliably observe perturbations arising from toxicity (Bonini and Fortini,
2003). Histological sections from one-week-old flies expressing pathogenic ataxin-3 with intact
VCP-binding show that there is already some disruption of the internal ommatidial array of the
eye compared to the control flies which did not express any ataxin-3 (Figure 4.5A, panel II
compared to panel I). Note the vacuolization of retinal structures when “Intact” pathogenic
ataxin-3 is expressed in the fly eye. By comparison, eyes expressing the “HNHH” version of
pathogenic ataxin-3 closely resemble control eyes, with a well-arranged ommatidial array and no
visible signs of degeneration or aggregated structures (Figure 4.5A, panels III and IV). As
SCA3 is a progressive disease, we expected to observe more degeneration as flies aged over the
course of four weeks. This is the case for four-week-old fly eyes expressing the “Intact”
pathogenic ataxin-3 protein, where we see substantial degeneration and loss of internal eye
structure (Figure 4.5B, panel II). We also observe densely-staining structures, indicative of
protein aggregates (red boxes; (Warrick et al., 2005; Warrick et al., 1998)). In "HNHH" eyes, we
also begin to observe degeneration and some densely-staining structures (Figure 4.5B, panels
III and IV). However, the ommatidial array is still clearly present and remains intact overall
through the course of the examinations.
We coupled histological assays with western blotting from dissected fly heads. Western
blots from one-day-old fly heads show the presence of ataxin-3 SDS-resistant species, as
indicated by the high molecular weight smears, when we probe with ataxin- 3 antibody (Figure
4.5C). We do not observe these species as prominently when the "HNHH" pathogenic ataxin-3 is
expressed in the fly eyes (Figure 4.5C). We conclude that mutating the VCP-binding site of
pathogenic ataxin-3 delays the formation of SDS-resistant species and slows the degeneration of
fly eyes, similar to what we observe when these ataxin-3 forms are expressed in other tissues.

62

Figure 4.6. Knockdown of VCP in fly eyes improves degeneration caused by pathogenic ataxin-3. In all panels, transgenes were
expressed using the eye-specific GMR-Gal4 driver. (A) Histological sections of four-week-old fly eyes expressing pathogenic ataxin-3 with or
without VCP RNAi. Vector Controls contained the GMR-Gal4 driver and empty pWalium10-moe vector on the same genetic background as
the RNAi lines. (B) Western blots of one-day-old fly head lysates when pathogenic ataxin-3 is expressed alone or with VCP RNAi in fly eyes.
Red dotted line: portion of SDS-resistant ataxin-3 species most clearly diminished in intensity by the knockdown of VCP. Black dotted line
was drawn consistent with the same line in blots from prior figures. Blots are representative of experiments repeated independently three times
with the same outcomes. (C) Quantification of VCP protein levels from panel B and other, independent repeats, in the presence or absence of
RNAi targeting VCP from four independent experiments. Means ± SD. Asterisks: P<0.05. P values are from two-tailed Student’s t-tests,

Altogether, the studies conducted in the various fly tissues with the different forms of
pathogenic ataxin-3 lead us to conclude that its binding to VCP influences the aggregation and
ensuing toxicity of pathogenic ataxin-3. To further probe into this model, we turned to
endogenous VCP.
4.2.6 Knockdown of VCP improves degeneration caused by pathogenic ataxin-3
The results that we obtained with our experiments above indicate that pathogenic ataxin-3
protein is less toxic when its VCP-binding site is mutated. We wanted to confirm these
differences in phenotype by targeting VCP itself. VCP is an essential protein with numerous
important functions in the cell. Knockdown of VCP in the whole fly, as well as in the nervous
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system, is developmentally lethal, but knockdown of VCP in fly eyes is well tolerated (our own,
unpublished observations). Thus, we examined whether knockdown of VCP in fly eyes
expressing pathogenic ataxin-3 with an intact VCP-binding site impacts the structure of the eye.
From histological sections at four weeks of age, as shown above (Figure 4.5B),
expression of “Intact” pathogenic ataxin-3 in the eyes using GMR-Gal4 is toxic and causes the
breakdown of the ommatidial array (Figure 4.6A). We used two different RNAi lines targeting
fly VCP. As shown in Figure 4.6C, knockdown of VCP by each RNAi line leads to statistically
significant reduction in VCP protein levels in the fly head. An important note here is that the
blots underestimate the extent of VCP reduction. This is because we target RNAi to the
Drosophila eyes, but, unable to isolate only the eyes, we examined protein levels from intact,
dissected fly heads, as is customary in fly studies.
Knockdown of VCP in fly eyes leads to improvement of pathology caused by ataxin-3.
As shown in Figure 4.6A, knocking down VCP with either RNAi-1 or -2 reduces ommatidial
disarray in the presence of pathogenic ataxin-3. VCP RNAi-1 is not as effective as RNAi-2 at
suppressing the degenerative phenotype. This could be due to the extent of VCP knockdown.
RNAi-1 targeting VCP consistently provides reduction of VCP protein based on western blots,
whereas the extent of knockdown with RNAi-2 is not as consistent, as indicated by the standard
deviation bars in Figure 4.6C. There may be a fine line between beneficial knockdown of VCP
to suppress ataxin-3-dependent pathology and too much suppression, which might be
problematic, on and of itself, to the eye since we are targeting a crucial gene. RNAi-1 might be
achieving this level of some improved pathology but also inherent toxicity due to low VCP
levels. Nevertheless, both RNAi lines present with improved pathology compared to pathogenic
ataxin-3 with intact VCP-binding in the absence of RNAi, supporting our model that the
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interaction between VCP and ataxin-3 is important for the toxicity of the SCA3 protein in vivo.
Concomitant with improved pathology, we observe reduced levels of SDS-resistant
species of ataxin-3 when VCP is knocked down (Figure 4.6B). In Figure 4.6B, and to a lesser
extent in earlier figures, a higher proportion of SDS-soluble ataxin-3 seems to be ubiquitinated in
flies when VCP is knocked down or the VCP-binding site is mutated. It is possible that when
ataxin-3 proteins bind to VCP they are brought in close proximity and deubiquitinate each other.
In conclusion, we observe decreased toxicity from ataxin-3 when VCP is knocked down
in fly eyes, indicating that VCP enhances ataxin-3 aggregation and toxicity.
4.2.7 Correlating ataxin-3 SDS-resistant species to fly longevity
Our results with the ubiquitous and pan-neuronal drivers show the presence of SDS-resistant ataxin-3 species with the “Intact” version before we observe marked lethality in flies. We
sought to further examine the temporal relationship between the SDS-resistant species and death.
In our previous experiments, expression of pathogenic ataxin-3 proteins (intact and impaired
VCP-binding) was driven throughout development and adulthood. In the next round of
experiments, we used fly genetics to initiate ataxin-3 expression after eclosion and for specific
points of time during adulthood to examine the correlation between fly death and and the
accumulation of SDS-resistant ataxin-3 species.
We used the tissue specific, inducible GeneSwitch Gal4 (Nicholson et al., 2008;
Osterwalder et al., 2001; Roman and Davis, 2002; Sujkowski et al., 2015). Using this system, the
pan-neuronal driver, elav-Gal4(GS) does not yield expression of ataxin-3 constructs until flies
are fed RU-486, the compound which activates the driver. In our setup, we reared flies that
harbor the driver and ataxin-3 constructs in fly media without RU-486, and then switched them
to RU-486-containing food on day 1 as adults. Offspring were then aged on RU-486-containing
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Figure 4.7. Correlation of ataxin-3 SDS-resistant species and longevity in flies. In all panels, transgenes were expressed using the panneuronal, RU-486-inducible elav-Gal4(GS) driver. (A, B) Western blots of fly lysates at the indicated ages (days) when pan-neuronal
expression of pathogenic ataxin-3 with intact or impaired VCP-binding was induced immediately upon eclosion from the pupal case. Blots in
each panel are from independent biological repeats. NS: non-specific band. Results are representative of experiments repeated independently
four or more times with the same outcomes. (C) Longevity of flies when pan-neuronal expression of pathogenic ataxin-3 with or without a
mutation on the VCP-binding site is induced upon eclosion from the pupal case.

media and collected for western blotting on day 1, 4, 7, 10, 14, 21, 28 and 35. During this time,
we also examined their longevity.
When pathogenic ataxin-3 with intact VCP-binding is driven by the RU-486-inducible
elav-Gal4(GS) driver, we begin to more clearly observe SDS-resistant species around days 4-7;
the intensity of these smears increases over time (Figure 4.7A). When expression of pathogenic
ataxin-3 with the “HNHH” mutation is induced, we observe SDS-resistant species more clearly
around days 10-14. These smears also increase in intensity over time (Figure 4.7A). When the
samples are compared side-by-side, on the same PVDF membrane, the difference in the timing
of appearance of SDS-resistant species among the two forms of ataxin-3 becomes noticeable
(Figure 4.7B). We observe comparable levels of SDS-resistant species between the two forms of
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pathogenic ataxin-3 around days 7 and 14 (“Intact” vs. "HNHH", respectively) and later, around
days 14 and 21 (“Intact” vs. "HNHH", respectively). Based on longevity curves, (Figure 4.7C),
temporally-induced expression of pathogenic ataxin-3 with impaired VCP-binding leads to
lethality at later time points than the version with intact VCP-binding, correlating with delayed
appearance of SDS-resistant species with the “HNHH” version of the SCA3 protein. These
results support our findings from various tissues that the “HNHH” mutation delays the
appearance of higher-molecular weight, SDS-resistant, ataxin-3-positive species in western blots,
as well as the toxicity of this protein, compared to the “Intact” version.
4.2.8 SDS-resistant species of pathogenic ataxin-3 are stable once formed
Lastly, we utilized the power of the RU-486-dependent elav-Gal4(GS) driver to examine
how stable the SDS-resistant species of pathogenic ataxin-3 are in vivo. We wondered if
eliminating the production of additional ataxin-3 could lead to time-dependent dissipation of the
protein itself, and if mutating its VCP-binding site influences this process. We have shown before
that ataxin-3 is a stable protein in the cellular environment (Todi et al., 2007). Thus, we chased
ataxin-3 for 14 days after we stopped its production by removing RU-486 from the fly media. To
begin with comparable levels of the SDS-resistant species, we induced pathogenic ataxin-3 with
an intact VCP-binding site for 14 days and the “HNHH” mutant form for 21 days in adult flies,
based on results from Figure 4.7B. Flies were reared in media without RU-486. They were
switched to media with the inducer on day 1 as adults (Figure 4.8A).
As shown in Figure 4.8B, the SDS-resistant species are stable for the 14 days that we
conducted our chases for both pathogenic ataxin-3 species. Whereas the SDS-soluble species
diminish in intensity over time, the intensity of the SDS-resistant species does not decrease.
Lastly, we tested if the physiological phenotypes of “Intact” and "HNHH" flies differ when the
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Figure 4.8. Ataxin-3 aggregates are stable, independently of VCP-binding capacity. In panels A-C, transgenes were expressed using the
pan-neuronal, RU-486-inducible elav-Gal4(GS) driver. (A) Outline of the experimental design for pulse-chases of pathogenic ataxin-3 with an
intact or mutated VCP-binding site. (B) Western blots from whole fly lysates where pan-neuronal expression of pathogenic ataxin-3 with or
without the VCP-binding mutation was induced and chased for the indicated time points. Blots are representative of experiments repeated
independently three times with the same outcomes. (C) Results from negative geotaxis assays assessing the motility of flies when pathogenic
ataxin-3 was induced and then chased. Ataxin-3(SCA3)-Intact was induced for 14 days, and Ataxin-3(SCA3)-HNHH was induced for 21 days.
Motility was assessed on Day 1, 21, and 28 of the flies’ total adult lifespan. Histograms represent means ± SD, expressed as a percentage. P
values are from two-tailed Student’s t-tests, comparing Ataxin-3(SCA3)-HNHH to Ataxin-3(SCA3)-Intact. No significant difference in motor
performance was found between Ataxin-3(SCA3)-Intact and Ataxin-3(SCA3)-HNHH. (D) Model: Ataxin-3 directly binds to VCP through the
VCP-binding site on its C-Terminal half. VCP acts as a nucleating agent and increases the local concentration of ataxin-3, leading to higher
chances of interaction and aggregation of the SCA3 protein.

aggregated species are present at comparable levels, following the same induction and temporal
parameters described above. In motility assays, we find no statistically significant difference
between the performance of flies expressing either version of pathogenic ataxin-3 (Figure 4.8C).
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Figure 4.9. Ataxin-3 aggregates formed earlier in the fly lifespan are also highly stable (Supplemental to Figure 4.8). (A) Outline of the
experimental design for pulse-chases of pathogenic ataxin-3 with an intact or mutated VCP-binding site. (B) Western blots from whole fly
lysates where pan-neuronal expression of pathogenic ataxin-3 with or without the VCP-binding mutation was induced and chased for the
indicated time points. Blots are representative of experiments repeated independently three times with the same outcomes. (C) Results from
negative geotaxis assays assessing the motility of flies when pathogenic ataxin-3 was induced and then chased. Ataxin-3(SCA3)-Intact was
induced for 7 days, and Ataxin-3(SCA3)-HNHH was induced for 10 days. Motility was assessed on Day 1, 21, and 28 of the flies’ total adult
lifespan. Histograms represent means ± SD, expressed as a percentage. Asterisk: P<0.05, compared to Ataxin-3(SCA3)-Intact flies.
P values are from two-tailed Student’s t-tests, comparing Ataxin-3(SCA3)-HNHH to Ataxin-3(SCA3)-Intact.

This suggests that the difference in motility phenotypes for the “Intact” and “HNHH” flies,
which we observed in Figure 4.4, is dependent on the different amounts of aggregated species,
rather than the intrinsic nature of the “Intact” vs "HNHH" proteins themselves. We also
conducted a similar experiment, with similar results, where we induced expression of pathogenic
ataxin-3 with an intact VCP-binding site for 7 days and mutated VCP-binding site for 10 days, to
address the possibility that aggregated species formed earlier and present at lower levels might
be more easily dispelled. This was not the case (Figure 4.9).
Altogether, the in vivo chase studies indicate highly stable aggregated species of ataxin-3
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and lack of a role for the VCP-binding site of ataxin-3 in their dissipation over time.
4.3 Discussion
We investigated the interaction of the SCA3 protein, ataxin-3, with its direct binding
protein, VCP, and the effect of this interaction in SCA3-like degeneration in Drosophila.
Ataxin-3 was reported previously to function with VCP to regulate degradation of ERAD
substrates (Wang et al., 2006; Zhong and Pittman, 2006). Interestingly, while ataxin-3 has been
ascribed various roles in cell culture-based studies, different knockout mouse lines that targeted
the atxn3 gene failed to show that this protein is a necessary entity in an intact mammal (Schmitt
et al., 2007; Switonski et al., 2011). Based on the knockout lines, we hypothesized some time
ago that targeting the ataxin-3 protein to enhance its degradation might have therapeutic benefits.
In those studies, we found that the VCP-ataxin-3 interaction did not impact the levels or turnover
rate of ataxin-3 degradation in cultured mammalian cells or in vivo in Drosophila (Blount et al.,
2014). We also found that the VCP-binding capability of ataxin-3 was dispensable for its role in
the fly, where the SCA3 protein serves a neuroprotective role (Tsou et al., 2015b). The VCPataxin-3 interaction was described in detail by the Wanker and Bonini groups over a decade ago.
In that work, Boeddrich et. al. reported that ataxin-3 and VCP bind each other directly through a
VCP-binding site on the C-terminus of ataxin-3 (Boeddrich et al., 2006). A model emerged
where binding of multiple ataxin-3 proteins by a single VCP hexamer brings SCA3 proteins in
close physical contact, thus expediting, or nucleating, early steps of their fibrillization. Intrigued
by that work and by our own findings that the VCP-ataxin-3 interaction does not impact the
degradation of ataxin-3 or its function in the fly, we investigated how this binding impacts
ataxin-3 aggregation and toxicity in vivo over time and in different tissues.
We found that accumulation of SDS-resistant species and insoluble aggregates occurs
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faster in flies expressing pathogenic ataxin-3 with an intact VCP-binding site than in flies
expressing pathogenic ataxin-3 with a mutated VCP-binding site. The SDS-resistant species that
we observe in western blots likely consist of lower- and higher-order multimeric species of
pathogenic ataxin-3. The insoluble pellet fractions we obtained from differential centrifugation
could contain higher-order ataxin-3 multimers and oligomers (O'Rourke et al., 2013). Coincident
with a delay in pathogenic ataxin-3 aggregation when its VCP-binding site is mutated (or when
VCP is knocked down in fly eyes), we noticed reduced toxicity from this version of the SCA3
protein, compared to the “Intact” form. In each of the studies we conducted, the form of ataxin-3
with impaired VCP-binding led to reduced toxicity, especially early on in the life of the flies. In
fact, at early stages, fly motility was entirely non-impacted by pathogenic ataxin-3 with impaired
VCP-binding. Later on, these flies did perform poorly when compared to flies not expressing the
SCA3 protein, but still much better than the “Intact” flies. Thus, while interrupting the
interaction between ataxin-3 and VCP had an ameliorative effect early on, in later stages the
disease protein still proved toxic. This is an important finding, as it suggests that VCP enhances,
but does not play a vital role, in the overall toxicity of the SCA3 protein. Also, from a therapeutic
point of view, interrupting the interaction of ataxin-3 with VCP might have beneficial effects, but
perhaps would not reach “curative” properties. The latter statement is further supported by the
data that inducing the expression of ataxin-3 only in adults still leads to premature death in flies,
and that mutating the VBM delayed lethality, but did not fully suppress it.
Collectively, our studies support a role for VCP in the early stages of ataxin-3
aggregation, consistent with a nucleation role for the hexamer put forth based on in vitro work
(Boeddrich et al., 2006) (Figure 4.8D). Non-pathogenic ataxin-3 itself has a propensity to
aggregate. This is believed to happen through a two-step process based on in vitro data with
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reconstituted systems using purified, recombinant proteins (Ellisdon et al., 2006; Masino et al.,
2011; Masino et al., 2004). Ataxin-3 that does not contain an expanded polyQ tract is thought to
first dimerize through the catalytic Josephin Domain in the structured N-terminus. In a second,
less understood step, the C-terminal tails of the proteins come together to create a ‘bead-on-astring’-type structure, and these further assemble into SDS-soluble protein aggregates (Ellisdon
et al., 2006; Masino et al., 2011). This process is also thought to occur in the same two-step
manner when ataxin-3 contains an expanded polyQ, although in that instance highly stable, SDSresistant aggregates form in vitro (Ellisdon et al., 2006; Masino et al., 2011). We propose that
VCP acts as a nucleating agent in initial ataxin-3 fibrillization. Ataxin-3 directly binds to VCP
through its VCP-binding site. A VCP hexamer could bind up to six ataxin-3 proteins (Boeddrich
et al., 2006; Xia et al., 2016). VCP, by binding to ataxin-3, increases the local concentration of
the protein and also increases the likelihood of binding between ataxin-3 molecules and eventual
formation into larger protein aggregates (Figure 4.8D). Inhibiting this interaction, or reducing
levels of VCP available for this step decreases aggregation and ensuing toxicity.
There was a recent study by the Loll lab that contradicts the model presented above.
Utilizing wild type (non-pathogenic) ataxin-3 and VCP proteins produced in bacteria, their in
vitro biochemical and electron microscopy work indicated that each VCP hexamer is bound by a
single, wild type ataxin-3 (Rao et al., 2017). Work by Wanker and Bonini hinted at a
stoichiometry of 4:1 ataxin-3:VCP (Boeddrich et al., 2006). Our own data in Drosophila are
consistent with a stoichiometry different than 1:1. It could be that the VCP:ataxin-3
stoichiometry is 1:1 for wild type ataxin-3, but different for pathogenic ataxin-3. Also, unlike in
an isolated system, it is possible that additional factors impact the stoichiometry between these
two proteins in vivo. This is an area that requires additional investigation in vivo.
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In summary, the VCP-binding site of ataxin-3 has a significant role on the aggregation
and toxicity of the SCA3 protein, underscoring the importance of non-polyQ domains in this
disease and pointing to the ataxin-3-VCP interaction as a potential therapeutic target. The model
for VCP-mediated fibrillization may extend beyond SCA3, since VCP also interacts with other
polyQ proteins (Fujita et al., 2013).
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CHAPTER 5: CONCLUSIONS
SCA3 is a devastating neurodegenerative disease for which the causative biology is
currently unknown. As such, ataxin-3’s non-polyQ domains and physiological functions can
provide us with valuable context for what mechanisms go awry in SCA3 and how to ameliorate
them. The Josephin domain, sumoylation at K166, and phosphorylation at several residues are
known to modulate toxicity of ataxin-3, but otherwise not much is known about how protein
context plays into SCA3. For this reason, we explored how ataxin-3’s interactions with Rad23
and VCP at specific binding sites can influence its disease properties.
We found that Rad23-binding at UbS2 regulates ataxin-3’s stability, autoprotective
function, and overall toxicity in vivo. Since reducing levels of polyQ proteins can be beneficial in
these diseases (Esteves et al., 2017; Keiser et al., 2016; Wang, 2017), lowering ataxin-3 stability
by targeting the Rad23-UbS2 interaction seemed like a reasonable therapeutic approach.
However, our results demonstrate the complexity of the Rad23-UbS2 interaction, since it
controls several of ataxin-3’s properties. Until more is known about how Rad23 regulates
ataxin-3’s neuroprotective function, this interaction is likely not a viable therapeutic target for
SCA3. As such, future work should focus on elucidating the mechanism for ataxin-3 and Rad23’s
upregulation of DnaJ-1. Experiments testing whether ataxin-3 and Rad23 bind directly to the
DnaJ-1 promoter, or influence the activity/stability of transcriptional regulators (HATs, HDACs,
transcription factors, etc.) would be an excellent place to start. Moreover, the discrepancies
between cell/fly and mouse studies emphasize the need to confirm these potential protective
mechanisms in mammalian systems. If ataxin-3 is not neuroprotective in humans, then disrupting
the Rad23-UbS2 interaction could be reconsidered as a potential therapeutic avenue.
Our work with VCP indicates that this protein can also influence ataxin-3 toxicity, but by
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a different mechanism. Our data suggests that VCP acts as a seeding factor for ataxin-3
aggregation, likely by bringing multiple ataxin-3 proteins in closer contact and increasing their
chances of aggregation. Mutating the VCP-binding site reduces ataxin-3 aggregation, which is
intriguing from a therapeutic perspective, since increasing solubility of polyQ proteins could
improve disease outcomes (Esteves et al., 2017; Wang, 2017). Decoy peptides that mimic the Nterminus of VCP may be a way to reduce both ataxin-3’s binding to endogenous VCP and
subsequent aggregation in vivo. To accomplish this, future experiments will aim to identify the
region of VCP’s N-terminus that most efficiently binds ataxin-3, while remaining stable in an in
vivo environment and without causing adverse toxicity. It will also be important to identify the
physical nature of the binding interaction between ataxin-3 and VCP, since the nucleation
hypothesis has not been formally confirmed.
The physiological purpose of ataxin-3’s interaction with VCP is not fully understood.
Past studies have linked ataxin-3 and VCP as potential partners in ERAD and the UPS, but the
molecular mechanisms remain to be clarified (Doss-Pepe et al., 2003; Wang et al., 2006; Zhong
and Pittman, 2006). Recently, VCP has been linked to defects in DNA repair in multiple polyQ
disorders (Fujita et al., 2013). Considering VCP and ataxin-3 are already known to co-localize at
sites of DNA damage (Ackermann et al., 2016), it would be very interesting to investigate if VCP
and ataxin-3 co-regulate DNA repair pathways. Moreover, Rad23 is also an established entity in
DNA repair (Dantuma et al., 2009). It is possible that these proteins might function as a complex
at the DNA, similar to their proposed role in the UPS (Doss-Pepe et al., 2003). Overall,
additional studies to elucidate the interplay between VCP, ataxin-3, and Rad23 will enhance our
appreciation for the physiological significance of these interactions in normal and disease states.
Ataxin-3 knockout studies report that the mice do not exhibit a decrease in viability or
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fecundity (Schmitt et al., 2007; Switonski et al., 2011). However, a complete characterization of
these models under stress and non-stress conditions remains to be conducted. Such studies could
reveal an essential role for ataxin-3 that was previously undetected. It is also possible that
another DUB is compensating for the loss of ataxin-3 in these models. The generation of
catalytically inactive ataxin-3 knock-in mice could enhance our understanding of ataxin-3’s
significance in protein quality control, DNA repair, and other pathways.
Finally, there are some notable similarities between our results and findings related to
other polyQ disorders, which were discussed in Chapter 1. Interestingly, the influence of UbS2Rad23 on ataxin-3’s stability is remarkably similar to the relationship between 14-3-3 and
ataxin-1 turnover (Chen et al., 2003). Moreover, the ability of the VCP-binding site to enhance
ataxin-3 aggregation is in agreement with multiple studies that demonstrate the ability of
domains flanking the polyQ tract to modify its solubility (Adegbuyiro et al., 2017; Nozaki et al.,
2001; Robertson and Bottomley, 2010). Thus, our findings related to SCA3 could have
implications for other polyQ diseases, and vice-versa. Undoubtedly, efforts to unravel the
complexities of protein context will be invaluable to understanding the biology of these diseases
and how to treat them. Moving forward, an appreciation for both the similarities and differences
between the polyQ disorders will facilitate new collaborative discoveries in the field.
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The polyglutamine (polyQ) disease family is composed of nine neurodegenerative
diseases caused by CAG trinucleotide repeat expansions in the associated genes. Although these
diseases are caused by similar mutations, the polyQ proteins are otherwise structurally and
functionally unique. Thus, the protein domains surrounding the polyQ tracts, as well as their
interacting partners, are thought to be critical to the pathogenesis of these clinically distinct
diseases. Spinocerebellar ataxia type 3 is caused by polyQ expansion of ataxin-3, a
deubiquitinating enzyme implicated in protein quality control, transcriptional regulation, and
DNA repair. Rad23 and VCP are two of ataxin-3’s protein quality control partners that bind at its
Ubiquitin-binding site 2 and VCP-binding site, respectively. To learn more about protein context
in SCA3, we generated new transgenic Drosophila lines that express pathogenic ataxin-3 with
these protein-binding sites intact or mutated. Through a battery of physiological and biochemical
assays, we observed that ataxin-3’s interaction with Rad23 regulates the stability, autoprotection,
and toxicity of the SCA3 protein. We also find that VCP can modulate the aggregation propensity
and subsequent toxicity of ataxin-3. Altogether, our findings provide insight into SCA3 biology
and potential avenues for therapeutic intervention.
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